

Swedish & Norwegian Testicular Cancer Projekt, SWENOTECA
Onkologiskt centrum, Lund, Sweden
Kontor for klinisk kreftforskning, Bergen, Norway

SWENOTECA VII

A revised continuation of SWENOTECA V

TESTICULAR SEMINOMA

CLINICAL STAGE I – SURVEILLANCE AND TREATMENT

CLINICAL STAGE IIA – RADIOTHERAPY

ADVANCED AND RELAPSED DISEASE



January, 2007

www.ocsyd.lu.se

Secretariats

Norway: Kontor for klinisk kreftforskning
Kreftavdelingen, Haukeland Universitetssykehus, 5021 Bergen

Sweden: SWENOTECA sekretariatet
Onkologiskt centrum, Universitetssjukhuset i Lund, 221 85 Lund

Drawing on front page: Eva Henriksson
ISBN 91-85738-76-X
Lund 2007

CONTENTS

	Page
Preface	4
<i>Flow sheet - Diagram of staging and treatment principles</i>	5
1 Background	7
2 Aim of the SWENOTECA VII treatment program	8
3 Diagnosis, pre- and post-orchiectomy examinations, clinical staging	8
4 Clinical staging, prognostic classification and risk grouping	11
5 Patient information and treatment decision	11
6 Principles of treatment of Clinical Stage I Seminoma	12
7 Treatment recommendations in Clinical stage I	12
8 Principles of Treatment in Clinical Stage IIA Seminoma.....	13
9 Treatment recommendations in Clinical stage IIA	13
10 Treatment of advanced seminoma (CS IIB – CS IV)	14
11 Treatment recommendations in advanced disease	14
12 Follow-up principles	15
13 Relapse	16
14 Monitoring and reporting the results of the program	17
15 Ethical considerations	17
16 References	18

ADDENDUM:

17 TNM - Pathological (p) and Clinical classification	21
18 Clinical staging	22
19 Prognostic classification	23
20 Patientinformation – svensk	24
21 Pasientinformasjon – norsk	27
22 Chemotherapy regimens: Carboplatin, EP, BEP, PEI, TIP.....	31
23 Radiotherapy	41
24 Carcinoma-in-situ of the testis	42
25 Follow-up schedule – Uppföljningschema.....	48
26 Abdominal Magnetic Resonance Imaging protocol for follow-up of patients operated for testicular cancer	49
Forms - blanketter	51

Information to be given to the patient at completed follow-up – to be completed during 2007, see <http://www.ocsyd.lu.se>

PREFACE

The Swedish & Norwegian Testicular Cancer Project, the SWENOTECA, started in 1981 with programs for staging, treatment and follow-up of non-seminomatous germ cell cancer.

The first program for testicular seminoma, SWENOTECA V, was introduced in 2000.

This is the second seminoma program, SWENOTECA VII, introducing risk adapted adjuvant treatment for localized seminoma.

Flow-sheet

Seminomatous Germ Cell Testicular Cancer, SWENOTECA VII

Testicular tumour

Ultrasound both testicles

Physical examination

History of prior testicular disorders and hereditary information



Tumour markers: AFP, β -HCG, LDH, PLAP (optional)

Hormone levels: Testosterone, LH, FSH, SHBG

Spermcount & cryopreservation (recommended)

Inguinal orchietomy and biopsy contralateral testicle



CIS → See addendum 24

Seminomatous testicular cancer (seminoma)

AFP normal (<1.5 normal range, repeated and stable values)

Risk factors: **Rete testis invasion**

Size of tumour > 4 cm



Clinical staging procedure

Tumour markers post-op: β -HCG, AFP, LDH (PLAP)

Spermcount & cryopreservation, (consider if not done earlier).

Chest X-ray, CT scan of thorax, abdomen and pelvis

TNM-classification



Treatment

Clinical stage I disease (CS I)

0–1 risk factor → **surveillance** or carboplatin x 1

2 risk factors → **carboplatin x 1** or surveillance

Option: radiotherapy to para-aortic nodes 2 Gy x 10 to 20 Gy. (For patients with previous inguinal or scrotal surgery, or T4 tumour, see addendum 23 Radiotherapy)

Clinical stage IIA disease (CSIIA)

Radiotherapy 1.8 Gy x 15 to 27 Gy to para-aortic and ipsilateral iliac nodes, or 4 x EP chemotherapy

Clinical stage \geq IIB (CS IIB–IV)

4 courses of EP-chemotherapy. If contraindications to chemotherapy or small tumour volume, treatment with radiotherapy to para-aortic and ipsilateral iliac nodes 1.8 Gy x 20 to 36 Gy might be an option in stage IIB. In very advanced disease BEP chemotherapy should be used.

Send in the SWENOTECA registration form to the national secretariat. After treatment, send in the treatment form. Follow-up according to schedule, see addendum 25. Send in FU forms after each follow-up.

In case of relapse – new full staging. Histological verification of relapse if possible.

1 Background

1.1 General information

Testicular tumours accounts for about 1% of all male malignancies and are in 95% of germ cell origin. (1) Seminoma constitutes approximately 50% of all germ cell tumours and is increasing in incidence. (2) The peak incidence occurs between thirty and forty years of age. Data from the Swedish and Norwegian cancer registries show an increase in seminoma from about 90 cases annually in Sweden (1983–1987) to about 150 (2004) and from about 75 cases annually in Norway (1983–1987) to about 150 (2004).

Little is known about etiological risk factors for the development of testicular tumours. Ten percent of the patients have had a history of cryptorchidism. Some epidemiological studies show a significantly increased percentage of pure seminoma as compared to germ cell tumours of other histologies in men with undescended testis. (3) Other risk factors are hypotrophic testicle and infertility. (4)

At the time of diagnosis, about 85% of the patients will be in clinical stage I and IIA. Due to a high radiosensitivity, seminoma has for decades been documented to be curable by radiotherapy in early stages. A surveillance policy for clinical stage I and treatment only in the case of relapse has in observational studies shown the same total cure rate of about 98%. (5) In a recent large randomised study of 1447 pts in stage I (no T4 tumours), with a median follow up of 4 years, comparing one course of adjuvant carboplatin chemotherapy with adjuvant radiotherapy, outcome was found to be similar with a relapse rate of 3–4% and no serious acute side effects. (6) The pattern of relapse differed with more abdominal retroperitoneal relapses after carboplatin chemotherapy compared to those treated with radiotherapy who experienced more relapses outside the retroperitoneal field. The development of highly effective chemotherapy has improved the curability also for advanced disease, and the total cure rate is now above 95%.

1.2 International guidelines for the treatment of CSI

Recently the European Germ Cell Cancer Consensus Group (EGCCCG) as well as the EAU-guidelines group list surveillance, carboplatin and radiotherapy as equivalent treatment alternatives. (7, 8)

1.3 SWENOTECA experience

During April 2000–Nov 2005, about 850 patients with seminoma in all stages have been included in the SWENOTECA V program. Median follow-up time is about 37 months (4–67). Median age at orchiectomy was 36 years. Median size of the testicular tumours was 3.6 cm (1.2–8.7). About 87% of the patients were in stage I. Patients in clinical stage I had the choice between adjuvant radiotherapy or surveillance. In Norway 40% of the 201 patients were treated with adjuvant radiation therapy versus 62% of the 475 Swedish patients. Recurrence in clinical stage I patients were seen in 13 patients on surveillance in Norway, and 1 patient in the radiation group, i.e., 10.7% and 1.3%, respectively; and in 13 (7.3%) of the Swedish patients on surveillance, and in 2 patients treated with radiation therapy (0.7%). Almost all recurrences were in the paraaortic lymph nodes. Median time to relapse was 10 months (range 3–44 months).

1.4 Follow up

Follow up is important, especially in surveillance patients. It is equally important in patients treated with carboplatin until data on long-term follow-up emerge. More than 80% of the relapses both for stage I and II seminoma occur within two years, as in non-seminoma. However few, late relapses after more than six years of surveillance have been reported and

the long-term relapse rate with adjuvant carboplatin is unknown. (9–12) Follow up is therefore recommended up to 10 years for these patients.

1.5 Aim

SWENOTECA VII is a cancer care program for seminomatous germ cell tumours in all stages in Sweden and Norway (part of). It is a continuation of the SWENOTECA V program and has mainly been revised with regard to treatment options in clinical stage I.

2 Aim of the SWENOTECA VII treatment program for patients with seminomatous testicular cancer

- To establish a complete register including all adult patients with seminomatous testicular cancer in Norway and Sweden.
- To standardise investigation procedures, staging and risk estimates, treatment and follow up.

2.1 Clinical stage I

- To compare the outcome of patients treated with one cycle of carboplatin with patients with no adjuvant treatment concerning acute and late toxicity, relapse rate and time to relapse and survival.
- To confirm published data on relapse rate for presumed low-risk patients on surveillance.
- To confirm published data on relapse rate after one course of carboplatin in presumed high-risk patients.

2.2 Advanced disease

- To evaluate treatment outcome, relapse rate and pattern of relapse and overall survival for patients treated with chemotherapy.
- To evaluate side effects after treatment for advanced disease.

3 Diagnosis, pre- and post-orchiectomy examinations, clinical staging

3.1 Diagnosis of Testicular Cancer

Testicular cancer usually presents as a painless, unilateral intrascrotal mass and is in the majority of cases diagnosed by palpation. Fewer than 10% will present clinical symptoms mimicking epididymitis.

Ultrasound of both the testicles should be performed, and exploration should be performed in all cases when non-invasive investigations cannot exclude a tumour.

Transscrotal fine needle aspiration or biopsy from the tumour should not be performed.

3.2 Serum tumour markers in seminoma

In contrast to non-seminomatous germ cell cancer, seminoma patients often lack elevated tumour markers.

Human chorionic gonadotropin (HCG) is slightly/moderately elevated depending on tumour volume in 20–50% of the patients. (13) A HCG-value of more than 200 IU should raise the suspicion of non-seminomoutous germ cell components and the specimen should be reexamined.

Alphafoetoprotein, AFP is by definition not consistent with a seminoma diagnosis. The detection of significantly elevated levels of AFP implies that the tumour specimen should be reexamined with respect to non-seminomatous elements. Even if these are not found, the tumour should be considered and treated as a non-seminoma! However, one should be aware that reparative and infectious/viral processes of the liver may induce a slight increase in AFP. Rarely patients constitutionally may have an AFP level slightly above the normal range. A modest and **stable** AFP level might thus be compatible with a seminoma diagnosis.

Lactate dehydrogenase (LDH) is a widely distributed enzyme of glycolytic metabolism and is released by many tissue types following cell damage. Total serum LDH levels are elevated in about 80% of patients with metastatic seminomatous testicular cancer. (14)

Placental alkaline phosphatase (PLAP) is elevated in 50% of the patients with seminoma but is only analysed in a few laboratories in Sweden. The use of this marker is optional. PLAP may be falsely elevated in smokers.

3.3 Fertility measures and hormonal analyses

Cryopreservation of sperm should preferably be offered before orchietomy or otherwise before start of any therapy although the detrimental effect of adjuvant chemotherapy or limited para-aortic radiotherapy is probably much smaller than with para-aortic and ipsilateral iliac field radiotherapy. (15)

Sexual hormones (LH/FSH, testosterone and SHBG) should be analysed before and after orchietomi and during follow up. The serum for the hormone analyses should preferentially be taken in the morning or at least before noon (due to their circadian variations). It is important to detect and treat hormonal insufficiency both with regard to short- and long-term morbidity of hypogonadism.

3.4 Before orchietomy

- All patients should be offered pre-orchietomy sperm count with cryopreservation
- Serum levels of AFP, HCG, LDH, (PLAP)
- Serum levels of LH, FSH, testosterone and SHBG
- Ultrasound examination of both testicles
- General physical examination

3.5 Inguinal exploration and orchietomy

An incision similar to that performed in patients with inguinal hernia is done. The anterior wall of the inguinal canal is divided, and the vas and spermatic vessels are dissected free at the internal opening of the inguinal canal. In most cases there is no doubt of the diagnosis and the spermatic vessels and the vas are divided immediately. The testis and epididymis with their surrounding tunica vaginalis are pushed out of the scrotum and dissected free from the scrotal wall. If any doubt of the diagnosis, the spermatic cord is clamped before mobilization

of the scrotal content and the tunica vaginalis is opened for direct testicular inspection. Frozen sections may be unreliable and in most cases orchietomy should be performed without delay. The vas and the spermatic vessels are ligated and divided separately close to the peritoneal fold.

The specimen is immediately sent for definitive histology. If possible, send the specimen fresh on ice to the pathology department, otherwise place it in formalin. The urologist should not incise the specimen.

3.6 Biopsy of the contralateral testis

Biopsy of the contralateral testis should be done because of the risk of cancer in situ (CIS), and this is best done at the time of the orchietomy (see Addendum, chapter 24). The testis should be held firmly and a transscrotal incision is made laterally on the tunica vaginalis, long enough to see it clearly. After incising the parietal layer, make a small incision in the tunica albuginea to allow testicular tubules to bulge out. Snip off a tuft of tubules cleanly with fine sharp scissors. Place the biopsy at once into a specimen pot containing formalin. While performing the biopsy, careful handling and placement in fixative is important to prevent mechanical damage. If it is of importance to evaluate not only CIS but also spermatogenesis, the biopsy must be put in Bouin's solution. Close the incision in the tunica and skin separately with interrupted 4–0 absorbable sutures.

3.7 Pathological examination of the testis

Macroscopic features and sampling:

- Side, testis size, **tumour size** and the macroscopic features of the tumour, such as macroscopic involvement of epididymis, spermatic cord and tunica vaginalis.
- Sampling: 1 cm² section for every cm of maximal tumour diameter, including normal macroscopic parenchyma (if present), tunica albuginea and epididymis selection of suspected areas. At least one proximal and one distal section of spermatic cord, plus any suspected area.

Microscopic features and diagnosis:

- Histological type, and specification of individual components according to the 2004 WHO classification.
(Comment: Spermatocytic seminoma is a distinct tumour of uncertain histogenesis and occurs in elderly patients. The benign character and good prognosis of the spermatocytic variant of seminoma should be acknowledged. (16) This seminoma entity is not included in the current protocol.)
- Presence or absence of **rete testis invasion**.
- Presence or absence of tumoural vascular invasion, tunica albuginea, tunica vaginalis, epididymis or spermatic cord invasion.
- Presence or absence of intratubular germinal neoplasia in non-tumoural parenchyma.
- pT category according to TNM 2002
see addendum
- Immunohistochemical studies of seminomas are rarely indicated, except in those cases that are overgrown by lymphocytes, resembling lymphoma. PLAP is invariably positive.

3.8 Clinical staging

- Serum levels of AFP, β-HCG, LDH (PLAP optional)
- Chest X-ray
- CT of thorax, abdomen/pelvis should be performed shortly after orchiectomy. If there is clinically any indication of advanced metastatic disease it should be done before orchiectomy.

If there is evidence of metastatic disease, the patient should be referred immediately to a regional oncology department for further evaluation and treatment.

3.9 Diagnostic radiography

Chest x-ray and CT-scan of the chest and abdomen/pelvis are mandatory in the staging procedure of all testicular cancers. PET scan is a sensitive and specific method to detect seminoma in abdominal nodes but is not to be used as a routine staging procedure. (17–18) Other investigations according to symptoms. Isolated skeletal involvement does occur in seminoma, although rare.

4 Clinical staging, prognostic classification and risk grouping

- Clinical staging according to the RMH staging system (**addendum 18**)
- Prognostic classification according to IGCCCG and MRC (**addendum 19**)
- Risk grouping in clinical stage I according to the presence of none, one or two of the risk factors: tumour size > 4cm, invasion of rete testis.

5 Patient information and treatment decision

The written information (**addendum 20, 21**) regarding the treatment options for patients in stage I must be given to the patient with adequate time for remaining questions. The patient should always be offered a new consultation within a short time. Furthermore, written information should be given of the registration in the SWENOTECA database, and of external (SWENOTECA) monitoring of the case records.

In Norway the written information must be signed by the patient.

In Sweden the patient's consent is noted in his case records.

The patient should be treated and followed according to the same principles even if he does not consent to be registered with full name in the database.

Immediately after the informed consent has been given, and treatment or surveillance is decided, the SWENOTECA “Registreringsblankett” should be sent to:

- Kontor for klinisk kreftforskning, Kreftavdelingen, Haukeland Universitetssykehus, 5021 Bergen (Norwegian patients)
- Onkologiskt centrum, Universitetssjukhuset i Lund, 221 85 Lund (Swedish patients)

6 Principles of treatment of Clinical Stage I Seminoma

6.1 Surveillance

More than 80% of the patients in CSI will not need any treatment and since the rescue rate with chemotherapy early on is almost 100%, surveillance has emerged as an attractive strategy. Risk factors for relapse were in 2002 identified by pooling data from the four largest surveillance studies comprising 638 patients from four centers: Royal Marsden Hospital, Danish Testicular Cancer Study Group, PMH and the Royal London Hospital. From this retrospective study of risk factors for relapse after surveillance, tumour size > 4 cm and rete testis invasion emerged as independent adverse prognostic risk factors. (23) The overall risk of relapse with a median follow up of 7 years was 20%, with a 12.2%, 15.9% and 31.5% risk for none, one or two risk factors respectively.

6.2 Carboplatin

A new adjuvant approach is chemotherapy with single agent carboplatin. (5, 24–26) Carboplatin monotherapy with one or two cycles has been shown to reduce the relapse rate effectively in non-randomised trials. In a single center study Steiner et al treated 108 patients with two cycles of carboplatin (400 mg/m^2) and only 2 (1.85%) relapsed, both in the retroperitoneum within the first year after a median follow up of 5 years. (27) The treatment was well tolerated with mild thrombocytopenia and mild gastrointestinal side effects.

Recently results from the large randomised trial of Oliver et al in 2005 were reported. In 1477 patients with a median follow-up of 4 years, one cycle of carboplatin (AUC 7) showed non-inferiority compared with radiotherapy regarding relapse-free survival. (6) Acute side effects were more pronounced after radiotherapy. Patterns of relapse differed with more abdominal retroperitoneal relapses after carboplatin chemotherapy (74% of the relapses) than after radiotherapy (9% of the relapses). Long-term results are however still lacking.

Dosage schedule of carboplatin: see addendum 22.

6.3 Radiotherapy

Until now standard adjuvant treatment of CSI seminoma has been radiotherapy to the para-aortic lymph nodes and the ipsilateral iliac nodes, hockey stick field, or dog-leg field which also include the inguinal nodes, or surveillance with treatment only in case of relapse. Efforts have been made to minimize the radiation field and dose in order to decrease the risk for potential long time side effects. The MRC Trial TE 10 randomised patients to either 30 Gy in 15 fractions given to a para-aortic field or given as a classical dog-leg field. No difference in overall relapse rate was found, but more pelvic recurrences were seen in the group treated with para-aortic field. However, reduced haemathological-, gastrointestinal- and gonadal toxicity was found in this group. (19) The study excluded patients with pT4 tumours and previous inguinal or scrotal surgery. The MRC Trial TE 18 compared 30 Gy given in 15 fractions versus 20 Gy given in 10 fractions to the para-aortic field and found them equally effective. (20) The relapse rate after adjuvant radiotherapy is low, 1–3%. (21–22)

7 Treatment recommendations in Clinical Stage I

Based on the results of adjuvant treatment with one cycle of carboplatin compared with standard radiotherapy and the identified risk factors for relapse, the SWENOTECA propose a risk-adapted strategy for treatment of CSI seminoma. (6, 23)

- For low-risk patients with 0–1 risk factors surveillance is recommended. The patient may also choose to receive 1 course of carboplatin.
- For high-risk patients with 2 risk factors adjuvant treatment with one course of carboplatin is recommended. The patient may also choose surveillance.
- Adjuvant radiotherapy is recommended for those who by any means are not suitable for chemotherapy or surveillance. **See addendum 23**
 - ⇒ Radiotherapy to the para-aortic field with 20 Gy given in 10 fractions is recommended.
 - ⇒ Radiotherapy should be given to para-aortic and ipsilateral iliac nodes in patients not able to fulfil adequate follow-up
 - ⇒ In patients with T4 tumours or previous ipsilateral, inguinal or scrotal surgery, radiotherapy to para-aortic, ipsilateral iliac and inguinal nodes should be considered.

8 Principles of Treatment in Clinical Stage IIA Seminoma

Radiotherapy, background

In CSII A a major concern is to accurately define the disease as truly metastatic i.e. if nodes are involved or not when visualized. The progression of disease is slower than in non-seminomatous cancer and repeated CT scans does not easily give an answer and biopsy might be difficult in nodes less than 1.5 cm. PET scan could be used to confirm involvement and several studies indicate a high sensitivity and specificity in seminoma. (17)

With limited disease (<2 cm) in the abdominal nodes, radiotherapy given to a para-aortic and ipsilateral iliac field is standard treatment. According to data in the literature a target dose of 25–30 Gy results in excellent local control with a relapse free survival of 95%. (28–30)

The remaining testis receives 1–3% of the total radiation dose. Doses less than 0.5 Gy usually cause a transient oligospermia, while higher doses cause azoospermia. If the dose is less than 1.5 Gy, a recovery is seen within 2 years. (31) Shielding of the remaining testicle **should** be used.

Other concerns relate to data on long-term morbidity, such as increased risk for cardiovascular events and increased risk of second malignancies. (32–34) However, all of these reports refer to patients irradiated to larger target volumes and radiation doses.

9 Treatment recommendations in Clinical Stage IIA

The target volume includes the para-aortic and ipsilateral iliac lymph nodes to a target dose of 27 Gy with 1.8 Gy per fraction x 15. **See addendum 23.**

10 Treatment of advanced seminoma (CS IIB – CS IV)

Background

There are no randomized studies on patients with stage IIB disease comparing radiotherapy and chemotherapy. The reported relapse rate with radiotherapy varies between 9–24%. All available data are based on small series of patients. (28, 35–37) The relapses after radiotherapy are predominately located outside the retroperitoneum. (28, 35–37) Even if the risk factors for subclinical disseminated disease in stage IIB disease are unknown it is reasonable to believe that tumour volume is of importance. Both radiotherapy and chemotherapy are viable alternatives.

For higher stages of seminoma there is international consensus on treatment with multiple courses of cisplatin based combination chemotherapy. (7,8) As patients with advanced seminoma are infrequent there are no randomised studies comparing different kinds of cisplatin-based chemotherapy. However, these patients were often included in protocols for low risk testicular cancer irrespective of histology. Results from these studies have shown that 4 EP is as effective as other cisplatin regimens. (38) No studies support the use of single agent carboplatin chemotherapy in advanced disease. (39–40)

In the International Germ Cell Consensus Classification (**see addendum 19**), a prognostic factor-based classification system for metastatic germ cell cancers, metastatic seminoma is classified as good or intermediate prognosis. No seminoma patients are classified as poor risk. Adverse prognostic factors are non-pulmonary visceral metastases, especially liver or brain. Also, presence of supra clavicular nodes and raised LDH (>two times the upper limit of normal) added negative prognostic information. (13, 41)

Seminomatous tumours are often characterised by slow clinical regression rate following chemotherapy. Residual tumour mostly consists of fibrotic or necrotic tissue. (7, 42–45) In post-chemotherapy seminoma residuals, a positive PET is highly predictive for the presence of viable tumour especially when using a ≥ 3 cm cut-off. A negative PET scan is excellent for the exclusion of disease in lesions ≥ 3 cm. PET can contribute to the management of residual seminoma lesions, especially in terms of avoiding unnecessary additional treatment for patients with non-regressing lesions ≥ 3 cm. (17–18, 46)

11 Treatment recommendations in advanced disease

- Four courses of EP (etoposide, 100 mg/m² d 1–5 d + cisplatin 20 mg/m² d 1–5) is recommended for good risk patients.
- If contraindications to chemotherapy or small tumour volume, treatment with radiotherapy to para-aortic and ipsilateral iliac lymph nodes, 1.8 Gy x 20 to 36 Gy might be an option in stage IIB.
- For patients in the intermediate prognostic group according to the IGCCCG, (extra-lymphatic, extra-pulmonary metastasis) 4 courses of BEP chemotherapy is recommended. PEI chemotherapy may be an option in patients with risk factors for bleomycin toxicity such as age > 40, decreased kidney and pulmonary function.
- Dose reduction and treatment delay should be avoided.
- Evaluation of response should be performed after 2 courses of therapy.

Residual mass

- Post-chemotherapy surgery or consolidating radiotherapy without histological verification of seminoma is not indicated.
- It is not possible to give exact recommendations of how often patients with residual tumour should be checked. There are no solid data on factors predicting viable tumour after cisplatin-based chemotherapy.
- Patients with regressing or persisting radiological findings after primary chemotherapy should be monitored with an appropriate radiological method (CT, MRI, US) and serum tumour markers.
- Check ups should be more intense the first 6 months, i.e. every second-third month.
- A PET scan is recommended if the residual mass is ≥ 3 cm and not regressing in order to identify viable seminoma in a residual mass. It should not be performed earlier than 2 months after completion of therapy due to the risk of false positivity.
- If positive PET scan, histological verification should be performed before consolidating therapy is decided upon. If viable tumour is found either radiotherapy or surgical removal of the tumour may be discussed.
- In case of stable residual mass with a negative PET scan no further measure has to be taken.
- Post-chemotherapy radiotherapy in case of viable residual tumour should be given to limited fields and to a total dose of 36–40 Gy given with 2 Gy fractions.
- In case of progressive residual tumour, histological confirmation has to be performed before salvage therapy is started. Progressive disease after initial therapy is treated either with surgery, radiotherapy or second line chemotherapy based upon individual data.

As these situations are rare it is recommended to discuss within the SWENOTECA network how to handle these patients.

12 Follow-up principles

All seminoma patients are to be followed closely according to the follow-up schedule specified (**see addendum 25**). Follow-up during year 1–2 is at 4-monthly intervals, year 3–4 every six months and year 5–10 once a year except for patients treated with adjuvant radiotherapy who are followed for a total of 6 years. In patients treated with adjuvant radiotherapy radiological investigation of abdominal lymph node stations should be performed **only** at month 24. For those treated with para-aortic field only, **pelvic radiology** should be done **yearly**. In case of residual masses follow-up should be intensified. The follow-up schedule should be modified according to metastatic sites.

After completed follow-up (6 and 10 years respectively), a written patient information with regard to long-term effects should be given to the patient (go to www.ocsyd.lu.se).

It is generally desirable to reduce the radiation dose from repeated diagnostic imaging procedures to the patient without compromising the quality of follow-up. Ultrasound examination or magnetic resonance imaging (MRI) of the abdominal and pelvic lymph node areas may be performed when suitable. If there is any ambiguity, a computed tomography (CT) examination must be performed. CT or MRI is recommended at least once yearly. The

clinician has to choose the best technique available at the respective centre and when necessary, refer the patient to another more specialized centre. If MRI is used the principles of the imaging protocol in **addendum 26** must be followed. A dialogue with the responsible radiologist is necessary to make sure that the principles of the protocol and reasons for the follow-up is fully understood.

18F Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) or PET/CT are still not established as routine imaging techniques in seminoma but may be used in special situations. PET can contribute to the management of residual seminoma lesions, especially in terms of avoiding unnecessary additional treatment for patients with non-regressing lesions ≥ 3 cm. For the evaluation of residual tumour a PET scan should not be performed earlier than 2 months after completion of therapy because of the risk of false positivity. (46)

Hormonal status is measured before and after orchietomy and at 1, 3, 5 and 10 years or when needed.

The SWENOTECA VII seminoma follow-up form must be filled in and sent to the national SWENOTECA secretariat, preferably after each visit, or **at the least once a year** for the relapse free patient.

If some of the follow-up consultations are referred to a local hospital, the responsible SWENOTECA clinician must ensure that good compliance to follow-up can be continued, and that any relapse is reported promptly to the SWENOTECA secretariat.

13 Relapse

In case of doubt, morphological verification should be performed.

Treatment depends on site of relapse and previous treatment. There are few reports on second line-chemotherapy, but long-term remission in about 50% of the patients has been reported. (47–49)

The SWENOTECA VII Follow-up form must be filled in, and sent to the national SWENOTECA secretariat immediately if a relapse is detected.

It is very important to detect any deviation from the postulated relapse rates and patterns as early as possible, in order to adjust the treatment and/or follow-up program, if indicated.

13.1 Relapse after surveillance or adjuvant carboplatin chemotherapy

In case of abdominal lymph nodal relapse < 2 cm in the surveillance group, radiotherapy 1.8 Gy x 15 to 27 Gy to para-aortic and ipsilateral iliac nodes is the treatment of choice. Chemotherapy is also possible (EP x 4), but not first choice.

Other relapses should be treated with 4 courses of EP-chemotherapy. In very advanced disease (intermediate risk) BEP chemotherapy should be used.

If contraindications to chemotherapy or small tumour volume (2–5 cm) in abdominal lymph nodal relapse, treatment with radiotherapy to para-aortic and ipsilateral iliac nodes 1.8 Gy x 20 to a total dose of 36 Gy might be an option.

13.2 Relapse after adjuvant radiotherapy

Relapses should be treated with 4 courses of EP-chemotherapy. In very advanced disease (intermediate risk) BEP chemotherapy should be used.

13.3 Relapse or progression after standard combination chemotherapy

Chemotherapy, surgery or radiotherapy may be applicable.

Chemotherapy with PEI (cisplatin 20 mg/m² d 1–5 + etoposide 100 mg/m² d 1–5 d + ifosfamide 1200 mg/m² d 1–5).

Chemotherapy with TIP (paclitaxel 250 mg/m², d 1 + ifosfamide 1500 mg/m² d 2–5 + cisplatin 25 mg/m² d 2–5). (49)

Radiotherapy 1.8 Gy per fraction to a total dose of 36–40 Gy.

13.4 High-dose chemotherapy

At present no data exist on high dose chemotherapy with stem cell support in seminoma patients in the salvage situation. Therefore in these rare situations we recommend discussions within the SWENOTECA network. See the SWENOTECA protocol for NSGCT for further information on procedures for drug administration.

14 Monitoring and reporting the results of the program

The SWENOTECA VII registration form must be sent to the national SWENOTECA secretariat immediately after inclusion and the SWENOTECA VII treatment form for patients receiving treatment at first follow-up visit after treatment. The SWENOTECA VII follow-up form should preferably be sent in after each follow-up visit or at least once a year if there is no relapse.

In cases of relapse it is important that a follow-up form regarding the relapse is sent to the national SWENOTECA secretariat as soon as possible.

A treatment form must be forwarded to the secretariat after completion of the salvage therapy.

15 Ethical considerations

Seminoma is curable close to 100% in patients with CS I and IIA disease. Surveillance in clinical stage I seminoma will result in a relapse in 20% of the patients all of which are expected to be salvaged by chemotherapy or radiotherapy. The over treatment of > 85% of the patients and the potential long-term sequelae with radiotherapy makes surveillance a reasonable option. Short course chemotherapy with one or two courses of carboplatin has changed the scenario offering an adjuvant treatment which is convenient and as effective as radiotherapy, at least with a median follow up of 4 years, but without presumed or few side effects. It is important to inform the patient of the risk factors and the available choices.

A common treatment protocol, a common quality database, and carefully performed monitoring of an experienced data management secretariat are important features in securing optimal survival in seminoma patients. The patients are, however, free to abstain from such external registration and monitoring.

16 References

- 1 Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. *J Urol* 2003;170(1):5-11.
- 2 Powles TB, Bhardwa J, Shamash J, et al. The changing presentation of germ cell tumours of testis between 1983 and 2002. *BJU Int* 2005;95(9):1197-2000.
- 3 Taran I, Elder JS. Results of orchiopexy for the undescended testis. *World J Urol* 2006 in press.
- 4 Raman JD, Nobert CF & Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. *J Urol* 2005;174(5):1819-22
- 5 Scholz M, Holtl W. Stage I testicular cancer. *Curr Opin Urol* 2003;13(6):473-6.
- 6 Oliver RT, Mason MD, Mead GM, et al: MRC TE 19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma. *Lancet* 2005;366(9482):293-300.
- 7 Schmoll HJ, Souchon R, Krege S, et al ; European Germ Cell Cancer Consensus Group. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCG). *Ann Oncol* 2004;15(9):1377-99.
- 8 Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer. *European Urology* 2005;48:885-94.
- 9 Chung P, Warde P. Surveillance in stage I testicular seminoma. *Urological Oncology: Seminars and Original Investigations* 2006;24:75-79.
- 10 Chung P, Parker C, Panzarella T, et al. Surveillance in stage I testicular seminoma – risk of late relapse. *Can J Urol* 2002;9(5):1637-40.
- 11 Dieckmann KP, Albers P, Classen J, et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. *J Urol* 2005;173(3):824-9.
- 12 Oldenburg J, Alfsen GC, Waehre, et al. Late recurrences of germ cell malignancies: a population based experience over three decades. *Br J Cancer* 2006;94(6):820-7.
- 13 Horwich A. Questions in the management of seminoma. *Clinical Oncology* 1990;2:249-53.
- 14 Fosså A and Fosså SD. Serum lactate dehydrogenase and human choriongonadotrophin in seminoma. *Br J Urol* 63:408-415, 984.
- 15 Reiter WJ, Kratzik C, Brodowicz T, et al. Sperm analysis and serum follicle-stimulating hormone levels before and after adjuvant single-agent carboplatin therapy for clinical stage I seminoma. *Urology* 1998;52(1):117-9.
- 16 Decaussin M, Borda A, Bouvier R, et al. Spermatocytic seminoma. A clinicopathological and immunohistochemical study of 7 cases. *Ann Pathol* 2004;24(2):161-6.
- 17 De Santis M, Pont J. The role of positron emission tomography in germ cell cancer. *World J Urol* 2004;22(1):41-6.
- 18 De Santis M, Becherer A, Bokemeyer C, et al. 18 fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumour in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. *J Clin Oncol* 2004; 22(6):1034-9.
- 19 Fosså SD, Horwich A, Russel JM, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumour Working Group. *J Clin Oncol* 1999;17(4):1146.
- 20 Jones WG, Fosså SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). *J Clin Oncol* 2005;23(6):1200-8.
- 21 Warde P, Gospodarowicz M, Pantarella T, et al. Surveillance is an appropriate management strategy in patients with stage I seminoma. *Int J Radiat Oncol Biol Phys* 2002;54:61.
- 22 Santoni R, Barbera F, Bertoni F, et al. Stage I seminoma of the testis: A bi-institutional retrospective analysis of patients treated with radiotherapy only. *BJU Int* 2003;92:47-52.
- 23 Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. *J Clin Oncol* 2002;20:4448-52.

- 24 Reiter WJ, Brodowicz T, Alavi S, et al. Twelve-year experience with two courses of adjuvant single agent carboplatin therapy for clinical stage I seminoma. *J Clin Oncol* 2001;19(1):101-4.
- 25 Aparicio J, Garcia del Muro X, Maroto P, et al. Spanish Germ Cell Cancer Cooperative Group (GG). Multicenter study evaluating a dual policy of postorchietomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. *Ann Oncol* 2003;14(6):867-72.
- 26 Aparicio J, Garcia del Muro X, Maroto P, Arranz JA & 15 others. Risk-adapted management for patients with clinical stage I seminoma: the second Spanish Germ Cell Cancer Cooperative Group. *J Clin Oncol* 2005; 23(34): 8717-23
- 27 Steiner H, Holtl L, Wirtenberger W, et al. Long term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single center study. *Urology* 2002;60(2):324-8.
- 28 Classen J, Schmidberger H, Meisner C et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. *J Clin Oncol* 2003;21:1101-06.
- 29 Zagars GK, Pollack A. Radiotherapy for stage II testicular seminoma. *Int J Radiat Oncol Biol Phys* 2001;51(3):643-9.
- 30 Warde P, Gospodarowicz MK, Panzarella T et al. Management of stage II seminoma. *J Clin Oncol* 1998;16(1):290-4.
- 31 Eberhard J, Stahl O, Giwercman Y et al. Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study. *Hum Reprod* 2004;19(6)1418-25.
- 32 Zagars GK, Ballo MT, Lee AK, et al. Mortality after cure of testicular seminoma. *J Clin Oncol* 2004;22(4);640-7.
- 33 Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40576 testicular cancer patients: Focus on long-time survivors. *J Nat Cancer Inst* 2005;97:1354-65.
- 34 Huddart RA, Birtle AJ. Recent advances in the treatment of testicular cancer. *Expert Rev Anticancer Ther* 2005;5(1):123-38.
- 35 von der Maase H. Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB? *Radiother Oncol* 2001;59(1):5-11.
- 36 Chung PW, Gospodarowicz MK, Panzarella T, et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. *Eur Urol* 2004;45(6):754-59.
- 37 Weissbach L, Bussar-Maatz R, Lohrs U, et al. Prognostic factors in seminoma with special respect to HCG: a result of a prospective multicenter study. Seminoma Study Group. *Eur Urol* 1999;36(6):601-8.
- 38 Mencel PJ, Motzer RJ, Mazumdar M et al. Advanced seminoma: treatment results, survival and prognostic factors in 142 patients. *J Clin Oncol* 1994;12(1):120-6.
- 39 Horwich A, Oliver RT, Wilkinson PM, Mead GM & 7 others. MRC Testicular Tumour Working Party. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Working Party. *Br J Cancer* 2000; 83(12):1623-9.
- 40 Bokemeyer C, Kollmannsberger C, Stennin S, Hartmann JT & 8 others. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combinationchemotherapy: a pooled analysis of two randomized studies. *Br J Cancer* 2004; 91(4):683-7.
- 41 Ghosh D, Fizazi K, Terrier-Lacombe M-J. Advanced seminoma – treatment results and prognostic factors for survival after first line, cisplatin-based chemotherapy and for patients with recurrent disease. A single-institution experience in 145 patients. *Cancer* 2003;98:745-52.
- 42 Puc HS, Heelan R, Mazumdar M, Herr H & 6 others. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. *J Clin Oncol* 1996; 14(2): 454-60.
- 43 Schultz SM, Einhorn LH, Conces DJ, Williams SD, Loehrer PJ. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. *J Clin Oncol* 1989;7: 1497-1503.
- 44 Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual mass in advanced seminoma. *J Urol* 2002; 168(5): 1975-9.

- 45 Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG. Postchemotherapy residual mass in advanced seminoma: current management and outcomes. *Expert Rev Anticancer Ther* 2005; 5(5): 869-74.
- 46 Becherer A, De Santis M, Karanikas G, Szabo M & 6 others. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. *Eur J Radiol* 2005; 54(2): 284-8.
- 47 Loehrer PJ, Sr, Gonin R, Nichols CR et al. Vinblastine plus ifosfamid as initial salvage therapy in recurrent germ cell tumour. *J Clin Oncol* 1998;16(7):2500-4.
- 48 Mead GM, Cullen MH, Huddard R et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second -line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research concil trial. *Br J Cancer* 2005;93(2):178-84.
- 49 Kondagunta VG, Bacik J, Donadia a et al. Combination of paclitaxel, ifosfamide, cisplatin is effective second-line therapy for patients with relapsed testicular germ cell tumors. *J Clin Oncol* 2005; 23: 6549-6555.

17 TNM - Pathological (p) and Clinical classification

T - Primary Tumour

The extent of the primary tumour is classified after radical orchiectomy; see pT.

pT - Primary Tumour

pTX Primary tumour cannot be assessed (if no radical orchiectomy has been performed, TX is used).

pT0 No evidence of primary tumour (e.g. histologic scar in testis).

pTis Intratubular germ cell neoplasia (carcinoma in situ).

pT1 Tumour limited to testis and epididymis without vascular/lymphatic invasion; tumour may invade tunica albuginea but not tunica vaginalis.

pT2 Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour extending through tunica albuginea with involvement of tunica vaginalis.

pT3 Tumour invades spermatic cord with or without vascular/lymphatic invasion.

pT4 Tumour invades scrotum with or without vascular/lymphatic invasion.

N - Regional Lymph Nodes

NX Regional lymph nodes cannot be assessed.

N0 No regional lymph node metastasis.

N1 Metastasis with a lymph node mass 2 cm or less in greatest dimension or multiple lymph nodes, none more than 2 cm in greatest dimension.

N2 Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, any one mass more than 2 cm but not more than 5 cm in greatest dimension.

N3 Metastasis with a lymph node mass more than 5 cm in greatest dimension.

M - Distant Metastasis

MX Distant metastasis cannot be assessed.

M0 No distant metastasis.

M1 Distant metastasis.

M1a Non-regional lymph node or pulmonary metastasis.

M1b Distant metastasis other than to non-regional lymph nodes and lungs.

18 Clinical staging: Modified after the Royal Marsden Hospital staging system

CS I No evidence of metastases

CS Mk+ β -HCG persistently elevated (not declining according to its half-time), but no metastatic disease demonstrated

CS II Metastatic disease restricted to abdominal nodes

- A Maximal transverse diameter <2 cm
- B Maximal transverse diameter 2–5 cm
- C Maximal transverse diameter >5–10 cm
- D Maximal transverse diameter >10 cm

CS III Supradiaphragmatic node involvement

For abdominal lymph nodes:

- 0 No metastases
- A–D According to CS II

CS IV Extra-lymphatic metastases

Lung substage:

- L1 ≤ 3 metastases, no metastases >2 cm
- L2 $>3 - \leq 20$ metastases, no metastases >2 cm
- L3 ≤ 20 metastases, >2 cm
- L4 >20 metastases

For abdominal lymph nodes:

- 0 No metastases
- A–D According to CS II

H+ Liver metastases

Br+ Brain metastases

Bo+ Bone metastases

19 Prognostic classification

Medical Research Council

Small volume disease: CS Mk+, II_{A-B}, III_{0-A-B}, L1-2

Large volume disease: CS II_{C-D}, III_{C-D}, IV_{C-D}, L1-L2

Very large volume disease: CS IV_{0-D}, L3-L4; extralymphatic extrapulmonary metastases (bone, liver, brain)

International Germ Cell Collaborative Consensus Classification

A prognostic factor-based staging system for metastatic germ cell cancers from the International Germ Cell Collaborative Consensus Classification Group (1997).

Non-seminoma	Seminoma
Good-prognosis group	
56% of non-seminomas	90% of seminomas
All of the following criteria:	All of the following criteria:
Testis/retroperitoneal primary	Any primary site
No non-pulmonary visceral metastases	No non-pulmonary visceral metastases
AFP <1,000 µg/L	Normal AFP
β-HCG <5,000 IU/L	Any β-HCG
LDH <1.5 x n	Any LDH
5-year survival 92%	5-year survival 86%
Intermediate-prognosis group	
28% of non-seminomas	10% of seminomas
All of the following criteria:	All of the following criteria:
Testis/retroperitoneal primary	Any primary site
No non-pulmonary visceral metastases	Non-pulmonary visceral metastases
AFP >1,000 and <10,000 µg/L or	Normal AFP
β -HCG >5,000 and <50,000 IU/L or	Any β-HCG
LDH >1.5 and <10 x n	Any LDH
5-year survival 80%	5-year survival 72%
Poor-prognosis group	
16% of non-seminomas	No patients classified as poor prognosis
All of the following criteria:	
Mediastinal primary	
Non-pulmonary visceral metastases	
AFP >10,000 µg/L or	
β-HCG >50,000 IU/L or	
LDH >10 x n	
5-year survival 48%	

Notes: AFP = alpha-fetoprotein; β-HCG = beta-human chorionic gonadotropin; LDH = lactate dehydrogenase

20 Patientinformation

SWENOTECA 2007-01-30

Information till patienter med testikelcancer av typ seminom utan tecken till spridning, stadium I.

Du har nyligen blivit opererad för cancer i testikeln. Mikroskopisk undersökning av tumören har visat att det rör sig om typen seminom. Utredning med blodprover och röntgenundersökningar har inte påvisat någon spridning av tumören och Din tumör klassificeras då som stadium I.

Hos en del patienter med testikelcancer i stadium I, kan det trots detta föreligga icke påvisbar spridning av tumörceller, oftast till lymfkörtlarna längs ryggraden i buken (hos ca 15–20 %). Hos dessa 15-20% av patienterna kommer sjukdomen att återkomma vilket upptäcks när tumörcellerna i lymfkörtlarna tillväxer. Hos enstaka patienter kan också sjukdomen sprida sig till andra organ.

Vad det gäller den fortsatta behandlingen för din sjukdom finns enligt europeiska riktlinjer tre alternativ: enbart kontroller tills tecken på eventuellt återfall, en kur med förebyggande cytostatikabehandling (cellgift), eller strålbehandling.

Idag kan man inte på förhand veta vilka patienter som utan tilläggsbehandling kommer att förbli friska (80–85 %), eller vilka som kommer få återfall av sin sjukdom (15-20 %). Med tilläggsbehandling minskar man risken för återfall men samtidigt behandlas de 80–85 % som ändå inte skulle fått återfall, i onödan.

Vid ett återfall av testikelcancer finns effektiv behandling. Oavsett vilket alternativ du väljer är prognosen god.

Riskanpassade behandlingsalternativ

Man vet idag att riskfaktorer såsom tumörstorleken (>4cm) och tumörens växtsätt (inväxt i kanalsystemet i testikeln) ökar risken för återfall. Behandlingsalternativen styrs av följande:

0-1 riskfaktorer:

Om man inte har någon riskfaktor (tumörstorlek, växtsätt) eller bara en av dem så är återfallsrisken ca 15%, varför enbart kontroller är ett alternativ vi rekommenderar.

Du har dock möjlighet att välja att få tilläggsbehandling om du så önskar (en kur cytostatika eller strålbehandling)

2 riskfaktorer:

Om man har båda riskfaktorerna är risken för återfall i sjukdomen ca 30%. Vår rekommendation är att man behandlar med en kur cytostatika i förebyggande syfte. Risken för återfall minskar från 30% till ca 5%.

Du har dock möjlighet att välja enbart kontroller eller eventuellt strålbehandling.

Behandlingsalternativ: för- respektive nackdelar

Enbart kontroller

Fördelen är att ingen behandlas i onödan. Man ger ingen efterbehandling, utan Du blir i stället noga kontrollerad, var fjärde månad de två första åren och därefter med glesare mellanrum under cirka 10 år. Nackdelen är att om man får ett återfall så blir behandlingen för detta mer omfattande än vid förebyggande behandling. Ett litet återfall i lymfkörtlarna i buken behandlas oftast med strålbehandling i 15 dagar. Annan typ av återfall behandlas med 4 cytostatikakurer (se nedan).

En cytostatikakur

En kort förebyggande cytostatikabehandling med ett läkemedel (Karboplatin), samt därefter kontroller med blodprov och röntgenundersökningar var fjärde månad de två första åren och därefter med glesare mellanrum under cirka 10 år. Behandlingen ges polikliniskt under ca 30 minuter i ett dropp i armens blodkärl. Den mest besvärande biverkan är illamående som dock till största delen förhindras av mediciner mot illamåendet. Antalet vita blodkroppar sjunker de första veckorna efter behandlingen vilket medför att man kan bli infektionskänslig. Även blodplättarna kan sjunka något, men sällan så att det får några konsekvenser för blodlevringen. Efter ca 3 veckor brukar man vara återställd. Behandlingen leder i allmänhet inte till hårväckning.

Fördelarna med att ge en kur med förebyggande cytostatika är att de flesta återfall förhindras, samtidigt som risken för bestående biverkningar efter en kur cytostatika är liten.

Strålbehandling mot lymfkörtaterna längs ryggraden i buken.

Strålbehandlingen pågår i två veckor (totalt 10 behandlingar med 5 behandlingar per vecka). En av biverkningarna vid behandlingen är illamående men detta kan vanligtvis förhindras med modern behandling mot illamåendet. Andra biverkningar kan vara trötthet och diarré. Kontroller sker regelbundet under cirka 6 år.

Risken för återfall i testikelcancer efter sådan strålbehandling är mindre än 5 %.

Det finns en viss risk för att denna behandling på lång sikt kan leda till en ny cancerform hos enstaka individer. Hur stor denna risk är vet man inte säkert då modern strålbehandling är olik den som man gav tidigare. Tidigare gavs en högre stråldos. Man vet därför inte säkert om de undersökningar, som har påvisat ökad förekomst av ny cancer gäller för dem som får behandling i dag med en lägre stråldos. Detta behandlingsalternativ förordas därför inte i första hand.

Cytostatikabehandling vid återfall:

Den cytostatikakur man använder vid ett eventuellt återfall benämns EP-kur (eventuellt BEP-kur) och består av två, (respektive tre) olika cytostatika. EP-kur ges som ett intravenöst dropp av medicinerna cisplatin och etoposid i fem dagar (vid BEP-kurer ges dessutom bleomycin en gång i veckan). Man vårdas inne på sjukhuset 5 dagar vid varje behandlingstillfälle. Det vanligaste är att man ger fyra kurer med tre veckors mellanrum.

All cytostatikabehandling ger akuta biverkningar, som någon enstaka gång kan vara allvarliga. Den mest besvärande biverkningen är oftast illamående och kräkningar. Detta kan som regel förhindras och alltid begränsas genom modern illamåendebehandling. Oftast kommer ett hårväckning två till fyra veckor efter den första cytostatikabehandlingen och efter 3 – 4 kurer kommer man att ha tappat allt hår. Håret växer ut igen några veckor efter att sista kuren givits. Antalet vita blodkroppar kommer att sjunka de första två veckorna efter behandlingen och man kan på grund att detta vara mer känslig för infektioner. Även andra blodvärden kan påverkas, men efter cirka tre veckor har de i allmänhet normaliserats. En del patienter känner en besvärande trötthet som kan vara bestående mellan kurerna och cirka en månad efter sista kuren.

Det är också känt att 3–4 cytostatikakurer kan ge kvarstående biverkningar i form av hörsel och njurfunktionsskador samt påverkan på fertiliteten.

De olika alternativen har sina fördelar och nackdelar således. Vi önskar därför att Du noga läser igenom denna information och funderar över vad Du tror skulle passa Dig bäst. Vi lägger stor vikt vid eventuella önskningar från den enskilde patienten.

Vi vill be om ditt tillstånd att, inom de sekretesskyddade databaser vi har, få registrera uppgifter som rör din sjukdom, behandlingen och förloppet av sjukdomen. Vi kan också vid behov behöva gå igenom dina journalhandlingar och tumörpreparatet, för att komplettera dessa uppgifter som vanligen lämnas på förtryckta blanketter. Denna registrering har betydelse för att möjliggöra kontinuerlig utvärdering av olika behandlingsalternativ, samt för att framöver kunna dra slutsatser som skall leda till att bästa tänkbara behandling ges till patienter med testikelcancer.

Om du inte samtycker skall du meddela detta till oss.

.....
kontaktperson

.....
telefonnummer

21 Pasientinformasjon

SWENOTECA 2007-01-30

Informasjon til pasienter med testikkellekreft av typen seminom uten tegn til spredning, stadium I.

Du har nylig blitt operert for kreft i testikkelen. Undersøkelse av svulsten har vist at det dreier seg om typen seminom. Utredning med blodprøver og røntgenundersøkelser har ikke påvist noen spredning og svulsten din klassifiseres da som stadium I.

Hos noen pasienter med testikkellekreft i stadium I, kan det likevel foreligge mikroskopisk spredning av svulstceller, som oftest til lymfeknutene langs ryggraden i buken (hos ca. 15–20%). Hos disse vil antall svulstceller i lymfeknutene øke, og senere kunne oppdages ved røntgenundersøkelser. Hos enkelte pasienter kan sykdommen også spre seg til andre organ.

Når det gjelder den videre behandling av din sykdom (etter operasjon av testikkelen), finnes det ifølge europeiske retningslinjer tre alternativ: 1. kun kontroller, 2. forebyggende behandling med en kur cellegift eller 3. forebyggende behandling med strålebehandling.

I dag kan man ikke på forhånd vite hvilke pasienter som uten tilleggsbehandling kommer til å forblie friske (80–85%), eller hvem som kommer til å få tilbakefall av sin sykdom (15–20%). Med tilleggsbehandling reduserer man risikoen for tilbakefall, men dette innebærer også unødvendig behandling av de 80-85 % som ikke vil få tilbakefall.

Om det tilkommer tilbakefall av testikkellekreften, finnes det effektiv behandling. Det betyr at uansett hvilket alternativ du velger er prognosene god.

Risikotilpassede anbefalinger

Man vet i dag at risikofaktorer som størrelsen av svulsten (>4 cm) i testikkelen og svulstens vekstmåte (innvekst i kanalsystemet i testikkelen) øker risikoen for tilbakefall. Anbefalt oppfølgings- evt. behandlingsstrategi styres etter følgende:

0-1 risikofaktorer:

Dersom man har ingen eller kun én risikofaktor (tumorstørrelse, vekstmåte), er tilbakefallsrisikoen ca. 15 %. I denne situasjonen vil vi anbefale kun kontroller.

Du har imidlertid mulighet til å velge å få tilleggsbehandling (én kur cellegift eller strålebehandlinger) dersom du ønsker dette.

2 risikofaktorer:

Dersom man har begge risikofaktorene er risikoen for tilbakefall av sykdommen ca. 30 %. I denne situasjonen er vår anbefaling én kur cytostatika i forebyggende hensikt. Risikoen for tilbakefall reduseres da fra 30 % til ca 5 %.

Du har imidlertid mulighet til å velge kun kontroller, eventuelt strålebehandling.

Behandlingsalternativer: fordeler og ulemper

Bare kontroller

Fordelen er at ingen behandles unødvendig. Man gir altså ingen etterbehandling, men du blir i stedet nøye kontrollert, hver fjerde måned de to første årene og deretter med lengre intervaller i cirka ti år. Ulempen er at dersom det kommer et tilbakefall, blir behandlingen for dette mer omfattende enn ved forebyggende behandling. Et lite tilbakefall i lymfeknutene i buken behandles likevel vanligvis med strålebehandling i 15 dager. Annen type tilbakefall behandles med 4 cellegiftkurer (se nedenfor).

En cellegiftkur

Dette innebærer behandling med én cellegiftkur (Karboplatin), fulgt av kontroller med blodprøver og røntgenundersøkelser hver fjerde måned de to første årene og deretter med lengre intervaller i cirka ti år. Behandlingen gis poliklinisk i løpet av ca. 30 minutter gjennom en vene på armen. Den mest besværende bivirkning er kvalme som i stor grad forebygges ved hjelp av kvalmestillende medisin. Antall hvite blodlegemer synker de første ukene etter behandlingen. Dette medfører at man kan bli mer utsatt for infeksjoner. Også blodplatene kan synke noe, men sjeldent så mye at dette medfører risiko for blødninger. Etter 2-3 uker er vanligvis blodverdiene normalisert. Behandlingen gir vanligvis ikke hårvfall.

Fordelene med å gi en forebyggende cellegiftkur er at de fleste tilbakefall forhindres, samtidig som risikoen for senere bivirkninger etter en kur med cytostatika er liten.

Strålebehandling mot lymfeknutene langs ryggraden i buken.

Strålebehandlingen pågår i to uker (totalt 10 behandlinger/5 behandlinger pr uke). En av bivirkningene ved behandlingen er kvalme, men dette kan vanligvis forebygges med moderne kvalmebehandling. Andre bivirkninger kan være tretthet og diaré. Oppfølgende kontroller pågår i 6 år.

Risikoen for tilbakefall av testikkellekreft etter slik strålebehandling er mindre enn 5 %. Det er en viss risiko for at denne behandlingen på lang sikt kan føre til en ny kreftform hos enkelte individer. Hvor stor denne risikoen er, vet man ikke sikkert fordi moderne strålebehandling er ulik den som ble gitt tidligere, da man ga høyere stråledoser. Man kan derfor ikke sikkert vite om de undersøkelser som har påvist økt forekomst av ny kreft, gjelder for dem som får behandling i dag med en lavere stråledose. Av denne grunn blir dette behandlingsalternativet ikke anbefalt som første valg.

Cellegiftbehandling ved tilbakefall

Den cytostatikakuren man bruker ved et eventuelt tilbakefall kalles EP-kur (eventuelt BEP-kur) og består av to (tre) ulike cytostatika. EP-kuren gis (gjennom blodet) i form av medikamentene cisplatin og etoposid i fem dager (ved BEP-kurer gir man dessuten bleomycin to ganger i uken). Man er innlagt i sykehus i 5 dager ved hver kur. Det vanligste er at man gir fire kurer med tre ukers mellomrom.

All cellegiftbehandling gir akutte bivirkninger, som enkelte ganger kan være alvorlige. Den mest ubehagelige bivirkningen er oftest kvalme og brekninger. Dette kan forhindres og alltid reduseres ved moderne kvalmebehandling. Oftest kommer det hårvfall to til fire uker etter den første cytostatikabehandlingen. Etter 3–4 kur er man miste alt hår. Håret begynner å vokse ut igjen noen uker etter siste kur.

Antall hvite blodlegemer kommer til å synke de første to ukene etter behandlingen, og man kan på grunn av dette være mer utsatt for infeksjoner. Også andre blodverdier kan påvirkes, men etter ca. tre uker er disse vanligvis normalisert. En del pasienter kan føle en plagsom tretthet som kan vedvare mellom kurene og ca. en måned etter siste kur.

Det er også kjent at 3–4 cytostatikakurer kan gi langtidsbivirkninger i form av hørsel- og nyrefunksjonsskader, samt gi redusert sædkvalitet.

De ulike behandlingsalternativer har sine fordeler og ulemper. Vi ønsker derfor at du nøye leser gjennom denne informasjonen og vurderer hva du tror er det beste alternativet for deg. Vi legger stor vekt på eventuelle ønsker fra den enkelte pasient.

Konfidensialitet og dataregistrering

Forskningsmedarbeiterne har taushetsplikt på linje med de som behandler deg i sykehuset. Dataregisteret er sikret mot uvedkommende innsyn etter retningslinjer i norske helselover.

Behandlingsprotokollen og dette informasjonsskriv er godkjent av Regional komité for medisinsk forskningsetikk.

Vi ber om din tillatelse til å få registrere relevante opplysninger omkring din sykdom, behandlingen og det videre sykdomsforløp. Disse opplysningene lagres i den sikkerhetsbelagte medisinske databasen som er opprettet ved Kontor for Kliniske Kreftforskning, Haukeland Universitetssykehus, Bergen. Vi ber også om din tillatelse til at forskningsmedarbeidere herfra kan se gjennom din journal for å komplettere og kontrollere de registrerte opplysninger. Slik registrering og kontroll er nødvendig for kontinuerlig å vurdere fordeler og ulemper ved ulike behandlingsalternativer, og dra erfaringer som kan lede til best mulig behandling for pasienter med testikkelkreft. Etter vår mening vil en slik løpende registrering og mulighet for ekstern kontroll innebære ekstra kvalitetssikring også for ditt eget etterkontroll-opplegg.

Du kan reservere deg mot en slik person-identifiserbar registrering og ekstern kontroll av dine journalopplysninger. Vi ønsker i så fall å kunne registrere relevante opplysninger om deg i databasen kun via et løpenummer, slik at din identitet kun er kjent av din behandelnde sykehusavdeling.

SAMTYKKEERKLÄRING

Jeg gir tillatelse til at medisinske opplysninger som er relevante for min behandling og etterkontroll av min sykdom registreres med mitt navn og personnummer i en medisinsk database ved Kontor for Klinisk Kreftforskning (KKK) ved Kreftavdelingen, Haukeland Universitetssykehus, Bergen.

Ved behov kan forskningsmedarbeider fra KKK få kontrollere relevante opplysninger i min sykehusjournal.

Navn..... den...../..... 20.....
blokkbokstaver

.....
signatur

Lege..... den...../..... 20.....
blokkbokstaver

.....
signatur

Karboplatin

Seminom, adjuvant behandling

Preparat	Dos/ dostillfälle mg/m ²	Maxdos/ dostillfälle mg	Antal doser/ dygn	Dos interv. tim	Antal doser/ cykel	Administreringssätt	Dag
1. Karboplatin	7x(GFR+25)*		1		1	iv inf 30 min	1

*totaldos

Calverts formel: Dos = AUC x (GFR + 25)

AUC = 7 mg/ml x min

GFR = ml/min, okorrigerat värde

Dos = mg, totaldos

Prep

1	1				Ny cykel	
					↓	
Dag	1					22

Cykellängd: 21 d

Beredning och administrering v g v

Speciella åtgärder

Iohexolclearance för beräkning av GFR före behandlingsstart. S-kreatinin före varje cykel.
Om s-kreatinin stiger >20 % görs iohexolclearence.

Dosreduktionsrekommendationer
Granulocyter × 10⁹/L TPK × 10⁹/L

Vid cykelstart:

<1.0

<100

Preparat, % av fulldos
1

Behandlingen uppskjutes

Anmärkning

Ingår i vårdprogram för seminom, SWENOTECA VII.

Karboplatin seminom

Blandning och administrering

Preparat	Blandas i ml	Administrering sätt	Sköljdropp tid	Spoldropp NaCl, ml	Kemiskt stabil	Kommentar
Karboplatin 5% glukos	250	iv inf	30 min	250		72 tim, kallt

EP**Testikelcancer, seminom**

Preparat	Dos/ dostillfälle mg/m ²	Maxdos/ dostillfälle mg	Antal doser/ dygn	Dos interv. tim	Antal doser/ cykel	Administreringssätt	Dag
1. Etoposid	100		1		5	iv inf	2 tim
2. Cisplatin	20		1		5		

Prep

1	1	1	1	1	1
2	2	2	2	2	2

Ny cykel
↓

Dag	1	2	3	4	5	22
-----	---	---	---	---	---	----

Cykellängd: 21 d

Beredning och administrering v g v

Speciella åtgärder

S-kreatinin inför varje cykelstart. Om patologiskt utföres iohexol-clearance.

Cisplatin gives med forcerad diures.

CAVE! aminoglykosid skall ej givas under eller en månad efter cisplatinbehandling.

Dosreduktionsrekommendationer
Granulocyter × 10⁹/LTPK × 10⁹/L

		Preparat, % av fulldos	
		1	2
1.0–1.4	>50		Ge behandling med G-CSF efter
< 1.0	<50		Behandlingen uppskjutes, i första hand 3 dagar
Clearance: ml/min	70–79	100	100 dag 1–4
	60–69	100	100 dag 1–3
	< 60	100	***

***cisplatin ersätts med carboplatin doserat enl Calverts formel:

Totaldos carboplatin, mg = 7 (okorrigerat clearance ml/min + 25)

Ex. okorrigerat clearance = 50 ml/min. 7(50 + 25) = 525 mg. Carboplatin gives dag 1.

Dock om nedsatt njurfunktion beror på tumörobstruktion gives fulldos cisplatin.

Anmärkning

Ingår i vårdprogram för seminomatös testikelcancer.

EP

Blandning och administrering

Preparat	Blandas i ml	Administrering sätt	Sköljdropp NaCl, ml	Spoldropp NaCl, ml	Kemiskt stabil	Kommentar
			250			
Cisplatin Etoposid	1000 NaCl	iv inf	2 tim		72 tim rumstemp.	

Prehydrering:

1000 NaCl under 2 tim.

Hydrering under behandlingen:

500 ml Mannitol 15% gives under 1 tim parallellt med cisplatininfusion.

Under behandlingsdygngen gives ytterligare minst 2 000 ml vätska po el iv.

Posthydrering: dygnet efter sista cisplatininfusion minst 2 000 ml; om patienten ej själv kan dricka denna mängd, skall vätska givas iv.

Diuresen under behandlingsdygnet samt dygnet efter sista cisplatinbehandlingens skall vara >400 ml/4 tim.

BEP**Testikelcancer, Icke epithelial ovariancancer**

Preparat	Dos/ dostillfälle mg/m ²	Maxdos/ dostillfälle mg	Antal doser/ dygn	Dos interv. tim	Antal doser/ cykel	Administreringssätt	Dag
1. Bleomycin*	30 000 IE**		1		3	im/iv inj	1, 5, 16
2. Etoposid	100		1		5	iv inf	2 tim
3. Cisplatin	20		1		5		1-5

* då patienten erhållit en kumulativ dos bleomycin på 300 000 IE gives regimen utan bleomycin

** totaldos



Cykellängd: 21 d

Beredning och administrering v g v

Speciella åtgärder

S-kreatinin inför varje cykelstart. Om patologiskt utföres iohexol-clearance.

Cisplatin gives med forcerad diures.

CAVE! aminoglykosid skall ej givas under eller en månad efter cisplatinbehandling.

Bleomycin: om toxisk reaktion vid bleomycintillförsel (feber, frossa) gives steroider exempelvis Deltison 25 mg po eller 3–4 mg Betapred. Fortsättningsvis gives steroider profylaktiskt före bleomycin.

Dosreduktionsrekommendationer

Granulocyter × 10⁹/L TPK × 10⁹/L

Preparat, % av fulldos

1 2 3

1.0–1.4	>50	Ge behandling med G-CSF efter		
< 1.0	<50	Behandlingen uppskjutes, i första hand 3 dagar		
Clearance: ml/min	70–79	100	100	100 dag 1–4
	60–69	50	100	100 dag 1–3
	<60	50	100	***

***cisplatin ersätts med karboplatin doserat enl Calverts formel:

Totaldos karboplatin, mg = 7 (okorrigerat clearance ml/min + 25)

Ex. okorrigerat clearance = 50 ml/min. 7(50 + 25) = 525 mg. Karboplatin gives dag 1.

Dock om nedsatt njurfunktion beror på tumörobstruktion gives fulldos cisplatin.

Anmärkning

Ingår i vårdprogram för non-seminomatös testikelcancer.

Bleomycin: CAVE! Risk för allvarlig pneumonit föreligger. Var observant på tecken på pneumonit. Ökad risk vid ackumulerad totaldos >400 000 IE; hos äldre patienter; vid hög O₂-koncentration i inandningsluft; tidigare eller samtidig strålbehandling mot thorax; nedsatt njurfunktion.

BEP**Blandning och administrering**

Preparat	Blandas i ml	Administrering sätt	Sköljdropp NaCl, ml	Spoldropp NaCl, ml	Kemiskt stabil	Kommentar
Cisplatin			250			
Etoposid		1000 NaCl iv inf	2 tim		72 tim rumstemperatur	
Bleomycin		im			7 dygn, kallt	

Prehydrering:

1 000 NaCl under 2 tim.

Hydrering under behandlingen:

500 ml Mannitol 15% gives under 1 tim parallellt med cisplatininfusion.

Under behandlingsdugnen gives ytterligare minst 2 000 ml vätska po el iv.

Posthydrering:

dygnet efter sista cisplatininfusion minst 2 000 ml; om patienten ej själv kan dricka denna mängd, skall vätska givas iv.

Diuresen under behandlingsdugnet samt dygnet efter sista cisplatinbehandlingen skall vara >400 ml/4 tim.

PEI**Testikelcancer**

Preparat	Dos/ dostillfälle mg/m ²	Maxdos/ dostillfälle mg	Antal doser/ dygn	Dos interv. tim	Antal doser/ cykel	Administreringssätt	Dag
1. Cisplatin	20		1		5	iv inf	2 tim 1–5
2. Etoposid	100		1		5		
3. Ifosfamid	1200		1		5	iv inf	30 min 1–5
4. Mesna	240 (20% av ifosf dos)	1			5		
Mesna	480 (40% av ifosf dos)	2			10	po*	2 o 6 tim efter ifosfamid

*Om patienten inte *säkert* får i sig mesna po (kräks) gives samtliga 3 doser iv.
20% av ifosfamiddosen gives då timme 4 och 8.

Prep

1	1	1	1	1	1
2	2	2	2	2	2
3	3	3	3	3	3
4	4	4	4	4	4

Ny cykel

Dag	1	2	3	4	5		22
-----	---	---	---	---	---	--	----

Cykellängd: 21 d

Beredning och administrering v g v

Speciella åtgärder

S-kreatinin inför varje cykelstart. Om patologiskt utföres iohexol-clearance.

Cisplatin gives med forcerad diures.

CAVE! aminoglykosid skall ej givas under eller en månad efter cisplatinbehandling.

Dosreduktionsrekommendationer
Granulocyter × 10⁹/L **TPK × 10⁹/L**

Preparat, % av fulldos

	1	2	3	4
1.0–1.4	>50	Gebehandling med G-CSF efter		
< 1.0	<50	Behandlingen uppskjutes, i först hand 3 dagar		
Clearance: ml/min	60–69	100 dag 1–3	100	100 dag 1–4
	< 60	**	100	100 dag 1–4
				100 dag 1–4

**cisplatin ersätts med carboplatin doserat enl Calverts formel:

Totaldos carboplatin, mg = 7 (okorrigerat clearance ml/min + 25)

Ex. okorrigerat clearance = 50 ml/min. $7(50+25)=525$ mg. Carboplatin gives dag 1.

Dock om nedsatt njurfunktion beror på tumörobstruktion gives fulldos cisplatin.

Anmärkning

Ingår i vårdprogram för non-seminomatös testikelcancer.

PEI**Blandning och administrering**

Preparat	Blandas i ml	sätt	Administrering tid	Sköljdropp NaCl, ml	Spoldropp NaCl, ml	Kemiskt stabil	Kommentar
Cisplatin				250			
Etoposid	1000 NaCl	iv inf	2 tim			72 tim rumstemper.	
Ifosfamid	250 NaCl	iv inf	30 min			72 tim, kallt	
Mesna 1:a dos							
Mesna dos 2 och 3 gives om möjligt po							

Prehydrering:

1 000 NaCl under 2 tim.

Hydrering under behandlingen:

500 ml Mannitol 15% gives under 1 tim parallellt med cisplatininfusion.

Under behandlingsdagnen gives ytterligare minst 2 000 ml vätska po el iv.

Posthydrering: dygnet efter sista cisplatininfusion minst 2 000 ml; om patienten ej själv kan dricka denna mängd, skall vätska givas iv.

Diuresen under behandlingsdagnet samt dygnet efter sista cisplatinbehandlingens skall vara >400 ml/4 tim.

TIP**Testikelcancer. Salvage**

Preparat	Dos/ dostillfälle mg/m ²	Maxdos/ dostillfälle mg	Antal doser/ dygn	Dos interv. tim	Antal doser/ cykel	Administreringssätt	Dag	
1. Paclitaxel	250		1		1	iv inf	24 tim	1
2. Ifosfamid	1500		1		4	iv inf	2 tim	2-5
3. Mesna	300		1		4			
4. Mesna*	300		2		8	iv inj	tim 4 och 8 efter avslutad ifosfamidinf.	
5. Cisplatin	25		1		4	iv inf	1 tim	2-5

*Mesna: Kan även ges peroralt men då i **dubbel** dos (40% av ifosfamiddosen). Första dosen gives iv tillsammans med ifosfamid, de följande perorala doserna 2 och 6 tim efter avslutad ifosfamidinf.

Prep

1	1
2	2 2 2 2
3	3 3 3 3
4	4 4 4 4
5	5 5 5 5

Ny cykel
↓

Dag 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Cykellängd: 21 d

Beredning och administrering v g v

Speciella åtgärder

Paclitaxel premedicinering: 30 min före start av infusion gives inj. Betametason 12 mg iv, inj.

Clemastin 2 mg iv, inj. Ranitidin 50 mg iv.

Kontroll av puls och blodtryck före och 15 min efter start av infusion.

Akutbricka + PM för åtgärder vid akuta allergiska reaktioner skall vara tillgängliga. Läkare skall finnas nåbar på personsökte. Se även ”Handläggning av lindrig reaktion vid Taxolinfusion”.

Cisplatin: S-kreatinin inför varje cykelstart. Om patologiskt utföres iohexol-clearance.

Cisplatin gives med forcerad diures.

CAVE! aminoglykosid skall ej givas under eller en månad efter cisplatinbehandling.

G-CSF: 5 µg/kg gives från och med dag 7

Dosreduktionsrekommendationer

Neutrofilax 10⁹/L TPK × 10⁹/L

<0.5	≤ 75	Behandlingen uppskjutes
Clearance: ml/min	60–69	Cisplatin dosreduceras till 100% dag 1–3
	<60	Cisplatin ersätts med karboplatin doserat enl Calverts formel:

Totaldos karboplatin, mg = 7 (okorrigerat clearance ml/min + 25)

Ex. okorrigerat clearance = 50 ml/min. $7(50 + 25) = 525$ mg. Karboplatin gives dag 1.

Dock om nedsatt njurfunktion beror på tumörobstruktion gives fulldos cisplatin.

Anmärkning

JCO 2005, 23, 6549

TIP – Testikelcancer

Blandning och administrering

Preparat	Blandas i ml	Administrering sätt	Sköljdropp tid	NaCl, ml	Spoldropp NaCl, ml	Kemiskt stabil	Kommentar
Paclitaxel				250			
	1000 NaCl	iv inf	24 tim				48 tim, rumstemp
Ifosfamid				250			
Mesna 1:a dos	1000 NaCl	iv inf	2 tim				72 tim, kallt
Mesna följande doser		iv inj/po					
Cisplatin	500 NaCl	iv inf	1 tim				72 tim, rumstemp

Hydrering under behandlingsdyg 2–5:

500 ml 15% Mannitol gives parallellt med cisplatin inf under 1 tim.

Posthydrering:

2000 ml NaCl gives efter cisplatin infusionen

Diures under behandlingsdyg 2–5 skall vara >400 ml/4 tim.

23 Radiotherapy

Dose:

CSI: 2 Gy x 10, 5 days weekly to total dose of 20 Gy to the para-aortic lymph nodes.

Note: If T4 tumour or previous inguinal or scrotal surgery, treatment of the para-aortic, the ipsilateral common and external iliac, and the ipsilateral inguinal lymph nodes should also be considered.

CSII A: 1.8 Gy x15, 5 days weekly to total dose of 27 Gy to the para-aortic and the ipsilateral common iliac- and the external iliac lymph nodes

Patient position and fixation:

The patient is placed in the supine position, fixated according to local practice for reproducible positioning of the patient during the whole treatment process. Mark the orchietomy scar with a pewter thread. For patients in reproductive age a lead shield should be used to protect the contra lateral testis from external scattered radiation.

Radiotherapy treatment technique:

A CT-based 3-dimensional (3D) planned radiotherapy is mandatory. The CT based plan of the fields is generated based on vascular anatomy as the lymph nodes follow the vessels (aorta, vena cava inferior, ipsilateral renal vein, the common iliac and external iliac vessels).

Beam quality:

Minimum 6 MV photons can be used.

Target volumes and organs-at-risk (OAR) volumes:

Target volumes

GTV (Gross tumour volume) should be defined as the volume of any lymph node enlarged due to metastasis (i.e., CSIIA).

CTV (Clinical target volume) in the para-aortic region should include the para-aortic lymph nodes from the upper border of the 11th thoracic vertebra to the aortic division and is defined as the combined inferior vena cava and aorta volume including visible lymph nodes and any GTV with an additional margin of 1.4 cm in the anterior, lateral, inferior and superior directions. Similarly for the renal vein volume except for no expansion laterally.

If the ipsilateral common iliac- and the external iliac lymph nodes are to be treated (i.e. CS II), the CTV should be extended to include the combined volume of the common iliac and external iliac vessels to the level of the top of the obturator foramen, including visible lymph nodes and any GTV, with an additional margin of 1.4 cm in all directions.

In case of previous inguinal or scrotal surgery or a T4 tumour, inclusion of both the ipsilateral common iliac- and the external iliac lymph nodes and the ipsilateral inguinal lymph nodes with additional margins as described in the former passage should be considered.

ITV (internal target volume) should be identical to the CTV as organ movement can be neglected.

PTV (planning target volume) is defined according to the ICRU definition.

Organs at risk:

The volumes of both kidneys should be outlined in each CT image. No more than 25% of each kidney volume should receive more than 20 Gy.

24 Carcinoma-in-situ of the testis

Definition

Testicular carcinoma-in-situ (CIS) represents a specific histological pattern characterised by presence in the seminiferous tubules of cells possessing several cellular characteristics of malignancy: abundant, glycogen-rich cytoplasm, large irregular nucleus with coarse chromatin clumps, aneuploid DNA content and multiple nucleoli (Skakkebæk 1978). In typical cases, the CIS cells and normally looking Sertoli cells are the only cell types present in the tubules. However, in some cases the CIS cells can be spread among cells of normal spermatogenesis. The proportion of tubules containing CIS cells vary from few to near 100% and usually the CIS tubules are dispersed throughout the whole testis (Jacobsen GK. *et al.*, 1981).

Natural course

CIS was originally reported in two infertile men who subsequently developed testicular germ cell cancer (TGCC) (Skakkebæk 1972). Studies of infertile men as well as TGCC patients harbouring CIS in the contralateral testis indicated that following the diagnosis, 50% of the men develop invasive tumours in 5 years and 70% in seven years (Giwercman *et al.*, 1987). Spontaneous regression of CIS has not been reported, and it seems probable that the majority – if not all – cases of CIS progress into an invasive stage of TGCC (seminoma or non-seminoma).

Biological aspects

Epidemiological data and immunohistochemical studies indicate that CIS has its origin in the early foetal life (Jørgensen *et al.*, 1995; Møller and Skakkebæk 1997; Møller 1993). It has been suggested that CIS cells are foetal gonocytes which have undergone malignant transformation (Skakkebæk *et al.*, 1987). The aetiology behind arise of CIS and thereby TGCC is unknown. The rapid increase in the incidence of TGCC, which has taken place during the past few decades, indicates an impact of environmental and/or life style related factors affecting the individual already in early foetal life (Skakkebæk *et al.*, 2001). Mother smoking during the pregnancy and chemicals acting as ‘endocrine disrupters’ have been linked to the aetiology of the CIS. The fact that CIS probably arise in the early foetal life does also have practical clinical implications. Provided that the screening method has sufficient sensitivity (see below), if CIS is not found in an adult man, his subsequent risk of developing TGCC is negligible.

High risk groups

Danish studies have shown presence of CIS in 5–6% of men diagnosed with unilateral TGCC (von der Maase *et al.*, 1986). However, the high risk of CIS in the contralateral testis is not a Danish phenomenon only, since similar figure was also found in a German study (Dieckmann and Loy 1996). Unfortunately, corresponding figures from other countries are lacking.

Other high risk groups for CIS of the testis are: men with a history of cryptorchidism (2–3%) (Giwercman 1992); patients with infertility problem due to impaired testicular function (3% in men with non-obstructive azoospermia); men with an extragonadal germ cell tumours (up to 50%) (Daugaard *et al.*, 1987); individuals with intersex conditions and gonadal dysgenesis (rare conditions with very high risk of gonadal malignancy) (Müller 1987).

Clinical features

CIS of the testis does not present with any specific clinical features. Testes harbouring CIS may be atrophic but CIS can also be found in normal-size gonads. Testicular palpation can be associated with some tenderness but usually is not associated with any abnormal findings. There are no specific serum markers of CIS.

Testicular ultrasound

Recent data have indicated that *testicular microlithiasis (TM)* - detection of multiple, small hyperechogenic lesions in the testis – is associated with high risk of CIS (Lenz *et al.*, 1987; von Eckardstein *et al.*, 2001). Thus, in a study of 78 men with TGCC the predictive value of TM for the contralateral testis to contain CIS was 22.2% (Lenz *et al.*, 1996). Although a single case of CIS was found in a testis without TM, in such case the predictive value that the testis would not contain CIS was 97.6% (Lenz *et al.*, 1996). This result was confirmed in another study (von Eckardstein *et al.*, 2001).

Recommendations for use of ultrasound and its implications:

- 1) *TGCC patients*: since testicular biopsy can easily be performed in these men at the time of orchidectomy, ultrasound as a screening for CIS in the contralateral testis is not recommended. However, in rare cases where the biopsy performed at the time of orchidectomy fails ultrasound can be used for decision whether to repeat the biopsy (+TM) or not (- TM);
- 2) In men seeking for infertility and presenting with testicular atrophy (one or both testes with orchidometer measure below 15 ml) and/or history of cryptorchidism, testicular biopsy is indicated in case TM is found;
- 3) The clinical implications of finding TM in otherwise healthy men are yet unknown and the method is, therefore, not recommended as a general screening for early TGCC.

Diagnosis

The only reliable method of diagnosing CIS is performing open surgical biopsy (Dieckmann *et al.*, 1999). It has to be stressed that the sensitivity of a needle biopsy has not been investigated. In TGCC patients the biopsy can ideally be done at the time of orchidectomy. The risk of serious complications following open surgical biopsy is very low and significantly less than the probability of developing contralateral TGCC (Bruun *et al.*, 1987). **The advantage of diagnosing the malignancy at a pre-invasive stage is the possibility of preserving the testis and thereby the endogenous androgen production (Giwercman *et al.*, 1991)** (see below). It is recommended that the biopsy is performed in all men undergoing orchidectomy, since no clinical or laboratory test are sufficiently reliable to exclude TGCC patients not being at risk of having CIS.

A single biopsy, approximately 3 mm in diameter disclose CIS in 95% of the cases when this condition is present (Dieckmann *et al.*, 1999). Therefore, provided that the risk of contralateral CIS is 5%, if no CIS is found the risk of subsequent second testicular tumour is less than 0.3%. However, such high sensitivity in the diagnosis of CIS can only be obtained if: a) the tissue is properly handled; b) the diagnosis is performed by a pathologists experienced in this area. A double-biopsy procedure may yield an even higher disclosure rate up to 99% (Dieckmann *et al.*, 2006, European Urology in press).

Place the biopsy at once into a specimen pot containing formalin. While performing the biopsy, careful handling and placement in fixative is important to prevent mechanical damage.

If it is of importance to evaluate not only CIS but also spermatogenesis, the biopsy **must** be put in Bouin's solution.

For pathological investigation, routine haematoxylin-eosin staining is sufficient. However, immunohistochemical staining with use of an antibody against Placental-like Alkaline Phosphatase can facilitate the diagnosis. It is important that the whole tissue block is thoroughly investigated since such procedure minimise the risk of missing the diagnosis of focal CIS.

Management of CIS

- 1) Unilateral TGCC and CIS in the contralateral testis:
 - a) **In patients not receiving chemotherapy:** CIS cells can be eradicated by local irradiation given as 8 daily doses of 2 Gy (total dose – 16 Gy). Although some of the men subsequently develop androgen insufficiency, in more than 50% androgen replacement is not required, at least during the first years post-irradiation. **For details of radiation technique see page 47.**
 - b) **In patients receiving chemotherapy:** Platinum containing chemotherapy may eradicate CIS. However, patients with CIS may develop invasive cancer in spite of chemotherapy (Christensen et al., 1998). The safest alternative is to give local irradiation as indicated under (a). However, an alternative is to repeat the biopsy, 1–2 years after completion of chemotherapy, and perform ultrasound every 6 months until biopsy. If CIS cells are present, irradiation should be offered. However, it should be kept in mind that following chemotherapeutic treatment the CIS cells may be reduced in number without being completely eradicated. A double biopsy is therefore recommended as the sensitivity of a single testicular biopsy is, expected to be lower than the figures given above and the risk of late contralateral TGCC exists. Even if the rebiopsy is negative, testicular ultrasound should be performed once yearly during the follow-up;
- 2) *Patients with extragonadal disease and CIS in one testicle:* Orchidectomy of the affected testicle is recommended;
- 3) *Bilateral CIS:* Irradiation as indicated under 1 a;
- 4) *Unilateral CIS and no malignancy in the other testis:* Orchidectomy.

Guidelines for follow-up after testicular irradiation for CIS:

- Control testicular biopsy should be done 12–24 months after irradiation and should disclose Sertoli-cell only pattern. Presence of germ cells indicate failure of the radiotherapy;
- Serum levels of testosterone, SHBG, LH, FSH and oestradiol should be checked prior to the radiation therapy, 6 and 12 months after. Subsequently the tests should be repeated with 12–24 months interval. Symptoms of hypogonadism combined with subnormal or low normal (even men with testosterone levels within the reference interval can be hypogonadal) total and free (adjusted for SHBG level) testosterone as well as high LH can be indicative of need for androgen substitution;
- Testicular ultrasound should be performed 3 months after radiotherapy, and every second year during 10 years follow-up.

Treatment of CIS and preservation of fertility potential

Testicular irradiation will lead to eradication of all germ cells and permanent sterility. Therefore, if the patient has a wish of future fertility following precautions should be taken:

- If the patient has a partner, immediate wish of having a child and significant sperm output (this issue needs to be discussed with an andrologist) some months to few years of surveillance, while the couple is trying to obtain pregnancy can be recommended. During this period testicular palpation and ultrasound should be performed every 6th month;
- In other cases cryopreservation of sperms prior to irradiation is recommended;
- In case of azoospermia (no sperms in the ejaculate) and a strong wish of preservation of fertility, multiple testicular biopsies, and if intratesticular elongated spermatids are found, subsequent cryopreservation is an option to be discussed with the patient.

References

1. Bruun,E., Frimodt-Møller,C., Giwercman,A., Lenz,S., and Skakkebæk,N.E. (1987) Testicular biopsy as an outpatient procedure in screening for carcinoma-in-situ: complications and the patient's acceptance. *Int.J.Androl.*, **10**, 199–202.
2. Christensen,T.B., Daugaard,G., Geertsen,P.F., and von der Maase,H. (1998) Effect of chemotherapy on carcinoma in situ of the testis. *Ann.Oncol.*, **9**, 657–660.
3. Daugaard,G., Olsen,J., von der Maase,H., Rørth,M., and Skakkebæk,N.E. (1987) Carcinoma-in-situ testis in patients with assumed extragonadal germ-cell tumours. *Lancet*, 528–529.
4. Dieckmann,K.P., Souchon,R., Hahn,E., and Loy,V. (1999) False-negative biopsies for testicular intraepithelial neoplasia. *J Urol.*, **162**, 364–368.
5. Dieckmann,K.-P. and Loy,V. (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. *J.Clin.Oncol.*, **14**, 3121–3125.
6. Giwercman,A. (1992) Carcinoma-in-situ of the testis: screening and management. *Scand.J.Urol.Nephrol.*, **148 (suppl.)**, 1–47.
7. Giwercman,A., Berthelsen,J.G., Müller,J., von der Maase,H., and Skakkebæk,N.E. (1987) Screening for carcinoma-in-situ of the testis. *Int.J.Androl.*, **10**, 173–180.
8. Giwercman,A., von der Maase,H., Berthelsen,J.G., Rørth,M., Bertelsen,A., and Skakkebæk,N.E. (1991) Localized Irradiation of Testes with Carcinoma in Situ: Effects on Leydig Cell Function and Eradication of Malignant Germ Cells in 20 Patients. *J.Clin.Endocrinol.Metab.*, **73**, 596–603.
9. Jacobsen GK., Henriksen OB., and von der Maase,H. (1981) Carcinoma In Situ of Testicular Tissue Adjacent to Malignant Germ-Cell Tumors: A study of 105 cases. *Cancer*, **47**, 2660–2662.
10. Jørgensen,N., Rajpert-De Meyts,E., Græm,N., Müller,J., Giwercman,A., and Skakkebæk,N.E. (1995) Expression of immunohistochemical markers for testicular carcinoma *in situ* by normal human fetal germ cells. *Lab.Invest.*, **72**, 223–231.
11. Lenz,S., Giwercman,A., Skakkebæk,N.E., Bruun,E., and Frimodt-Møller,C. (1987) Ultrasound in detection of early neoplasia of the testis. *Int.J.Androl.*, **10**, 187–190.
12. Lenz,S., Skakkebæk,N.E., and Hertel,N.T. (1996) Abnormal ultrasonic pattern in contralateral testes in patients with unilateral testicular cancer. *World J.Urol.*, **14**, S55–S58.
13. Møller,H. (1993) Clues to the aetiology of testicular germ cell tumours from descriptive epidemiology. *Eur.Urol.*, **23**, 8–15.
14. Møller,H. and Skakkebæk,N.E. (1997) Testicular cancer and cryptorchidism in relation to prenatal factors: case-control studies in Denmark. *Cancer Causes Contr.*, **8**, 904–912.

15. Müller,J. (1987) Abnormal infantile germ cells and development of carcinoma-in-situ in maldeveloped testes: a stereological and densitometric study. *Int.J.Androl.*, **10**, 543–567.
16. Skakkebæk,N.E. (1972) Possible carcinoma-in-situ of the testis. *Lancet*, 516–517.
17. Skakkebæk,N.E. (1978) Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. *Histopathology*, **2**, 157–170.
18. Skakkebæk,N.E., Berthelsen,J.G., Giwercman,A., and Müller,J. (1987) Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. *Int.J.Androl.*, **10**, 19–28.
19. Skakkebæk,N.E., Rajpert-De Meyts,E., and Main,K.M. (2001) Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. *Hum.Reprod.*, **16**, 972–978.
20. von der Maase,H., Rørth,M., Walbom-Jørgensen,S., Sørensen,B.L., Christophersen,I.S., Hald T., Jacobsen GK., Berthelsen,J.G., and Skakkebæk,N.E. (1986) Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. *Br.Med.J.*, **293**, 1398–1401.
21. von Eckardstein,S., Tsakmakidis,G., Kamischke,A., and Nieschlag,E. (2001) Sonographic testicular microlithiasis as an indicator of premalignant conditions in normal and infertile men. *J Androl*, **22**, 818–824.

Behandling av kvarvarande testikel med elektroner

STRÅLKVALITÉ

Elektronenergi väljs så att **minimidosen** i testis är 16 Gy. Dos per fraktion: 2 Gy.

Uppläggning



För uppläggningen behövs ett stöd för blyskyddet (t.ex. en trekant av frigolit), 1 cm tjockt vattenekvivalent bolus, 0.8–1 cm tjockt blyskydd samt ytterliggare bolus (ej med på bilden). Blyskyddet och det bolus som skall placeras under testikeln har en halvmåneformad urfasning för bättre passform mot scrotum.



Patienten placeras i rygg läge med benen fixerade brett isär.

Placera blystödet (trekanten av frigolit) mellan benen. Närmast under testikeln placeras 1 cm vattenekvivalent bolus följt av ett 0.8–1 cm tjockt blyskydd. Blyskyddet kan med fördel bestå av flera tunnare skivor.



Tejpa undan penis uppåt. Kring testikeln placeras vattenekvivalent bolus med en utsträckning på minst 2 cm lateralt. Det är viktigt att bolusen har en så bra passform som möjligt.

Vid användandet av ”låga” elektronenergier kan det vara aktuellt att placera bolus även ventralt om testikeln.

25 Follow-up all seminoma patients

Schedule to be attached to patient chart, put date at checkpoint

Name: _____

ID-number: _____

Invasion rete testis: yes no Tumour size: _____

Surveillance Carboplatin RT-paraaortic RT-paraaortic+iliacal EP BEP Date end of treatment: _____

Type A: clinical invest, HCG, LDH, creatinin, AFP (optional), chest X-ray, abdominal and pelvic CT/MRI/US (see page 15 and 49)
(CT or MRI at least once yearly)

Type B: Like A plus, testosteron, SHBG, LH, FSH. Spermcount (optional)

NOTE!

Should be modified with regard to metastatic sites and residual tumour! Residual tumour after end of treatment should be followed with shorter intervals during the first 6 months (see page 15). PLAP is an optional tumour marker.

Patients in stage I treated with- paraaortic RT: pelvic CT/MRI is recommended yearly for six years, abdominal CT only month 24
- paraaortic + iliacal RT: abdominal and pelvic CT is needed only month 24

	A	A	B	1st year Months after treatment
0 = date end of treatment	4	8	12	
12	16	20	24	2nd year
24	30		36	3rd year
36	42		48	4th year
48			60	5th year
60			72	6th year


Patients in stage I treated with RT are followed for 6 years. Patients on surveillance or treated with adjuvant carboplatin, and patients treated for metastatic disease are followed according to type A year 7-10. Other investigations on indication.

After completed follow-up (6 and 10 years respectively), a written patient information with regard to long-term effects should be given to the patient (go to www.ocsyd.lu.se).

26 Abdominal Magnetic Resonance Imaging protocol for follow-up of patients operated for testicular cancer

	No obligatory preparations	\$		Option:	Four hours fasting, antiperistaltic drugs.					
	Phased-array or Body Coil				Saturation bands superior-inferior, anterior-posterior					
	Approximately 30 minutes examination time									
Philips Intera 1.5T	Scan name	Metod	Timing TR/TE/flip	Orientation phase enc dir	FOV (mm)	Matrix/ Scan%	Thickness/ gap (mm)	Coil	NSA	Comments
1	Cor STIR alt. Balanced FFE	STIR alt. FFE	1600/20	Cor/RL	485	100	5,0/0,5	Q-body	2	Whole abdomen large FOV
2	Ax T2 TSE resp trig	TSE	1800/100	Ax/AP	300-450	variable	5,5/0,5	Q-body	2	Upper abdomen from diaphragm to kidneys
3	Ax T1 dual echo	FFE/Dual-echo	150/2,3/4,6	Ax/AP	300-450	variable	5,5/0,5	Q-body	1	Upper abdomen from diaphragm to kidneys
4	Ax T2 TSE resp trig	TSE	1800/100	Ax/AP	300-450	variable	5,5/0,5	Q-body	2	Lower abdomen to symphysis pubis
5	Ax T1 dual echo	FFE/Dual-echo	150/2,3/4,6	Ax/AP	300-450	variable	5,5/0,5	Q-body	1	Lower abdomen to symphysis pubis
Siemens 1.5 T	Scan name	Metod	Timing TR/TE/flip	Orientation phase enc dir	FOV (mm)	Matrix/ Scan%	Thickness/ gap (mm)	Coil	NSA	Comments
1	tru-fisp fat sat	Gradient echo	5,39/2,7/80	Cor/RL	400	220x256	5,0/0,8	Body array+spine array	1	Whole abdomen large FOV
3	Ax T2 TSE resp trig	TSE	1620-193/150	Ax/AP	360	185x384	6,0/1,2	Body array+spine array	3	Upper abdomen from diaphragm to kidneys
4	Ax T1 FLASH resp trig	Gradient echo	1774,76/70	Ax/AP	360	173x384	6,0/1,2	Body array+spine array	2	Upper abdomen from diaphragm to kidneys
5	Ax T2 TSE	TSE	4070/109/150	Ax/AP	350	200x512	5,0/1,3	Body array+spine array	2	Lower abdomen to symphysis pubis
6	Ax T1 TSE	TSE	480/11/180	Ax/AP	350	188x512	5,0/1,3	Body array+spine array	2	Lower abdomen to symphysis pubis
option	Cor STIR	TSE	2000/59/150	Cor/RL	400	240x320	5,0/1,2	Body array+spine array	1	Whole abdomen large FOV
General Electric 1.5 T	Scan name	Metod	Timing TR/TE/flip	Orientation phase enc dir	FOV (mm)	Matrix/ Scan%	Thickness/ gap (mm)	Coil	NEX	Comments
1	Cor True FISP	True FISP	4-8/2-4	Cor/RL	480	100	5,0/0,5	Body Array	1	Whole abdomen large FOV
2	Ax T2 FSE	FSE	2-5000/100	Ax/AP	300-400	512x256	5,5/0,5	Body Array	2	Upper abdomen from diaphragm to kidneys
3	Ax T1	FSPGR alt SE	150-500/min	Ax/AP	300-400	512x256	5,5/0,5	Body Array	1- 2	Upper abdomen from diaphragm to kidneys
4	Ax T2 FSE	FSE	2-5000/100	Ax/AP	300-400	512x256	5,5/0,5	Body Array	2	Lower abdomen to symphysis pubis
5	Ax T1	FSPGR alt SE	150-500/min	Ax/AP	300-400	512x256	5,5/0,5	Body Array	1- 2	Lower abdomen to symphysis pubis

STIR-Short tau Inversion recovery, FFE- Fast field echo, TSE-turbo spin-echo, FSE- fast spin-echo. FSPGR- fast spoiled gradient echo
SE- Spin echo, Resp trig- Respiratory triggering, Cor-Coronal, Ax-transaxial, RL-right left, AP- antero posterior
Q-body - Quadrature body coil, FOV- Field of view, TR- Repetition time, TE- Echo time
NSA-Number of signal averages, NEX- Number of excitations



- a. Coronal STIR-sequence with limits for upper and lower abdominal transaxial acquisitions outlined
- b. Transaxial T2-weighted respiratory triggered turbo spin-echo sequence
- c and d. Transaxial T1-weighted breath-hold spoiled gradient-echo sequence with fat and water in- (c) and opposed (d) phase.

SWENOTECA VII, Seminom

Registreringsblankett

Svenska patienter	Norska patienter
SWENOTECA sekretariatet	Kontor for klinisk kreftforskning
Onkologiskt centrum	Kreftavdelningen
Universitetssjukhuset i Lund	Haukeland Universitetssykehus
221 85 LUND	5021 Bergen
Klinik, sjukhus	
Läkare	

Personnummer

Namn

Orchiektomi

<input type="checkbox"/> Nej <input type="checkbox"/> Ja	Kontralateral testisbiopsi <input type="checkbox"/> Cis <input type="checkbox"/> ej Cis <input type="checkbox"/> ej utfört	Spermiogram utfört <input type="checkbox"/> nej <input type="checkbox"/> ja, om ja: <input type="checkbox"/> före orchiektomi <input type="checkbox"/> efter orchiektomi			
Datum <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>år</td><td>mån</td><td>dag</td></tr></table>	år	mån	dag		
år	mån	dag			
Sjukhus Patolog avd	PAD nr <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>år</td><td>.....</td></tr></table>	år		
år				
Orchiektomi <input type="checkbox"/> hö <input type="checkbox"/> vä	Tumörstorlek <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>x</td><td>.....</td></tr></table> mm	x	
.....	x			
Inväxt i rete testis <input type="checkbox"/> nej <input type="checkbox"/> ja					
Vaskulär invasion <input type="checkbox"/> nej <input type="checkbox"/> ja <input type="checkbox"/> oklar	"Utbränd tumör" <input type="checkbox"/> nej <input type="checkbox"/> ja	Ifylls endast om tumörstorleken inte är angiven			

Tumörmarkörer

Före orchiektomi	AFP <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>,</td><td>.....</td></tr></table>	,	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> ej utfört			
.....	,							
Datum <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>år</td><td>mån</td><td>dag</td></tr></table>	år	mån	dag	β-HCG <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>,</td><td>.....</td></tr></table>	,	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> ej utfört
år	mån	dag							
.....	,							
	LD <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>,</td><td>.....</td></tr></table>	,	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> ej utfört			
.....	,							
	PLAP <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>,</td><td>.....</td></tr></table>	,	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> ej utfört			
.....	,							
Efter orchiektomi (vid definitiv stadieindelning)	AFP <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>,</td><td>.....</td></tr></table>	,	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> ej utfört			
.....	,							
Datum <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>år</td><td>mån</td><td>dag</td></tr></table>	år	mån	dag	β-HCG <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>,</td><td>.....</td></tr></table>	,	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> ej utfört
år	mån	dag							
.....	,							
	LD <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>,</td><td>.....</td></tr></table>	,	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> ej utfört			
.....	,							
	PLAP <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>,</td><td>.....</td></tr></table>	,	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> ej utfört			
.....	,							
Hormonstatus	Testosteron <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>,</td><td>.....</td></tr></table>	,	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> lågt <input type="checkbox"/> ej utfört			
.....	,							
Datum <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>år</td><td>mån</td><td>dag</td></tr></table>	år	mån	dag	SHBG	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> lågt <input type="checkbox"/> ej utfört			
år	mån	dag							
	LH	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> lågt <input type="checkbox"/> ej utfört						
	FSH	<input type="checkbox"/> normalt <input type="checkbox"/> förhöjt	<input type="checkbox"/> lågt <input type="checkbox"/> ej utfört						

Metastaser

Lymfkörtelmetastaser	Största metastas (mm x mm)	Extralymfatiska metastaser	Största metastas (mm x mm)						
Inguinalt <input type="checkbox"/> nej <input type="checkbox"/> ja	<table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>x</td><td>.....</td></tr></table>	x	Lunga <input type="checkbox"/> nej <input type="checkbox"/> ja	<table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>x</td><td>.....</td></tr></table>	x
.....	x							
.....	x							
Iliakalt <input type="checkbox"/> nej <input type="checkbox"/> ja	<table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>x</td><td>.....</td></tr></table>	x	Antal lungmetastaser <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td></tr></table>			
.....	x							
.....									
Paraaoortal <input type="checkbox"/> nej <input type="checkbox"/> ja	<table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>x</td><td>.....</td></tr></table>	x	Skelett <input type="checkbox"/> nej <input type="checkbox"/> ja				
.....	x							
Mediastinalt <input type="checkbox"/> nej <input type="checkbox"/> ja	<table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>x</td><td>.....</td></tr></table>	x	Lever <input type="checkbox"/> nej <input type="checkbox"/> ja				
.....	x							
Supraklav <input type="checkbox"/> nej <input type="checkbox"/> ja	<table border="1" style="display: inline-table; vertical-align: middle;"><tr><td>.....</td><td>x</td><td>.....</td></tr></table>	x	Hjärna <input type="checkbox"/> nej <input type="checkbox"/> ja				
.....	x							
		Annat <input type="checkbox"/> nej <input type="checkbox"/> ja	Lokal:						

Klinisk stadieindelning¹

<input type="checkbox"/> CSI Antal riskfaktorer ²	T-stadium pT4 ³	<input type="checkbox"/> CSII <input type="checkbox"/> CSIII <input type="checkbox"/> CSIV <input type="checkbox"/> CSMk+
<input type="checkbox"/> 0 <input type="checkbox"/> 1 <input type="checkbox"/> 2	<input type="checkbox"/> nej <input type="checkbox"/> ja	

Abdominella lymfkörtlar 0 A B C D**Gruppering enl MRC⁴** small large very large volume**Prognos enl IGCC⁵** god intermediär dålig**Behandling CSI** surveillance adj. Karboplatin adj. strålbehandling**Behandling CSII-IV** strålbehandling EP BEP

Annan, spec

Förklaringar till Registreringsblankett SWENOTECA VII, Seminom

1. Klinisk stadioindelning: modifierad efter RMH

CS I Inga tecken på metastaser

CS Mk+ β -HCG kvarstående förhöjd (faller ej enl sin halveringstid)
men inga metastaser påvisbara

CS II Metastaser begränsade till abdominella lymfkörtlar

A maximal diameter <2 cm

B maximal diameter 2–5 cm

C maximal diameter >5–10 cm

D maximal diameter >10 cm

CS III Metastaser i lymfkörtlar ovan diafragma

CS IV Extralymfatiska metastaser

För lungmetastaser gäller:

L₁ ≤3 metastaser, ingen >2cm

L₂ >3 – ≤20 metastaser, ingen >2cm

L₃ ≤20 metastaser, >2cm

L₄ >20 metastaser

För abdominella lymfkörtlar gäller:

0 inga metastaser

A–D enl ovan CS II

2. Riskfaktorer

Primärtumör >4 cm, inväxt i rete testis

3. pT4

Tumour invades scrotum with or without vascular/lymphatic invasion

4. Gruppering enl Medical Research Council

Small volume disease CS Mk+, II_{A–B}, III_{A–B}, IV_{0–A–B}, L_{1–L2}

Large volume disease CS II_{C–D}, III_{C–D}, IV_{C–D}, L_{1–L2}

Very large volume disease CS IV_{0–D}, L_{3–L4}; extralymfatiska extrapulmonella metastaser
(skelett, lever, hjärna)

5. International Germ Cell Consensus Classification

Good-prognosis group. All of the following criteria:

Any primary site

No non-pulmonary visceral metastases

Normal AFP

Any β -HCG

Any LDH

Intermediate-prognosis group. Any of the following criteria:

Any primary site

Non-pulmonary visceral metastases

Normal AFP

Any β -HCG

Any LDH

Poor-prognosis group

No patients classified as poor prognosis

SWENOTECA VII, Seminom Behandlingsblankett

Svenska patienter
SWENOTECA sekretariatet
Onkologiskt centrum
Universitetssjukhuset i Lund
221 85 LUND

Klinik, sjukhus

Läkare

Personnummer

Namn

Orsak till behandling						
<input type="checkbox"/> adjuvant	<input type="checkbox"/> metastatisk sjukdom	<input type="checkbox"/> recidiv				
Start av behandling						
<input type="checkbox"/> Kemoterapi	<input type="checkbox"/> År	<input type="checkbox"/> mån	<input type="checkbox"/> dag			
<input type="checkbox"/> Karboplatin	<input type="checkbox"/> EP	<input type="checkbox"/> BEP	<input type="checkbox"/> annat			
Strålbehandling			<input type="checkbox"/> annat	Antal kurer		
<input type="checkbox"/> paraaortalt	<input type="checkbox"/> paraaortalt + iliakalt	<input type="checkbox"/> annat				
Fraktionsdos	<input type="checkbox"/> , <input type="checkbox"/> Gy	Targetdos	<input type="checkbox"/> , <input type="checkbox"/> Gy			
Orsak till avslutad behandling						
<input type="checkbox"/> enligt program	<input type="checkbox"/> terapisvikt	<input type="checkbox"/> biverkningar	<input type="checkbox"/> annan, spec.....			
Toxicitet¹ Grad 3-4						
Hematol.	Hb	<input type="checkbox"/> nej	<input type="checkbox"/> ja	Perifer neuropati	<input type="checkbox"/> nej	<input type="checkbox"/> ja
	Vita	<input type="checkbox"/> nej	<input type="checkbox"/> ja	Obstipation	<input type="checkbox"/> nej	<input type="checkbox"/> ja
	Trombocyter	<input type="checkbox"/> nej	<input type="checkbox"/> ja	Infektion	<input type="checkbox"/> nej	<input type="checkbox"/> ja
Renal	S-kreat	<input type="checkbox"/> nej	<input type="checkbox"/> ja	Annan allvarlig toxicitet	<input type="checkbox"/> nej	<input type="checkbox"/> ja, spec
Effekt av behandling²						
<input type="checkbox"/> adjuvant beh	<input type="checkbox"/> CR	<input type="checkbox"/> PR	<input type="checkbox"/> SD	<input type="checkbox"/> PD	<input type="checkbox"/> ej evaluerbart	
Fortsatt behandling (nedanstående rutor ifylls när beslut fattats och eventuell tilläggsbehandling givits)						
<input type="checkbox"/> ingen	<input type="checkbox"/> kirurgi					
<input type="checkbox"/> konsoliderande strålbehandling	<input type="checkbox"/> högdoskemoterapi med rescue					
<input type="checkbox"/> kemoterapi, spec	<input type="checkbox"/> annan behandling, spec					
Konsoliderande strålbehandling (efter kemoterapi/kirurgi)						
Startdatum	<input type="checkbox"/> År	<input type="checkbox"/> mån	<input type="checkbox"/> dag			
Fraktionsdos	<input type="checkbox"/> , <input type="checkbox"/> Gy	Targetdos	<input type="checkbox"/> , <input type="checkbox"/> Gy			
Resttumör	<input type="checkbox"/> abdomen	<input type="checkbox"/> pulm	<input type="checkbox"/> annat, spec			
Kirurgi						
Datum	<input type="checkbox"/> År	<input type="checkbox"/> mån	<input type="checkbox"/> dag			
Orsak till kirurgi						
Resttumör	<input type="checkbox"/> abdomen	<input type="checkbox"/> pulm	<input type="checkbox"/> annat,			
Recidiv	<input type="checkbox"/> abdomen	<input type="checkbox"/> pulm	<input type="checkbox"/> annat,			
Annan orsak, specificera orsak och lokalisering,						
Sjukhus	Patolog avd			PAD nr	<input type="checkbox"/> , <input type="checkbox"/> , <input type="checkbox"/> , <input type="checkbox"/> , <input type="checkbox"/> - <input type="checkbox"/> År	
PAD						
<input type="checkbox"/> nekros/fibros	<input type="checkbox"/> seminom	<input type="checkbox"/> annat,				
Radikal operation			Kirurgisk allvarlig komplikation			
<input type="checkbox"/> nej	<input type="checkbox"/> ja	<input type="checkbox"/> nej	<input type="checkbox"/> ja, spec			
Fortsatt behandling efter ev. tilläggsbehandling (ny beh blankett ifylls vid behov)						
<input type="checkbox"/> ingen	<input type="checkbox"/> kirurgi	<input type="checkbox"/> högdoskemoterapi med rescue				
<input type="checkbox"/> kemoterapi	<input type="checkbox"/> strålbehandling	<input type="checkbox"/> annan behandling, spec				

Förklaringar till Behandlingsblankett SWENOTECA VII, Seminom

1. Gradering av toxicitet (WHO 1979)

	Grad 3	Grad 4
Hematologisk (vuxna)		
Hemoglobin g/L	65–79	< 65
Vita x 10 ⁹ /L	1,0–1,9	< 1,0
Trombocyter x 10 ⁹ /L	25–49	< 25
Urinvägar		
S-Kreatinin	5–10 x N	> 10 x N
Neurotoxicitet		
Perifer	Intolerabla parestesier och/eller uttalad svaghet	Förlamning
Obstipation*	Uppspänd buk	Uppspänd buk och kräkningar
Infektion	Svår infektion	Svår infektion med blodtrycksfall

N = Övre normalgränsen

* = Obstipation, inkluderar ej obstipation p g a morfinpreparat

2. Remissionsbedömning. Effekt av behandling

- Komplett remission: Fullständigt försvinnande av samtliga tumormanifestationer på CT/MR eller motsvarande. Normala tumörmarkörer.
- Partiell remission: Reduktion av mätbar tumor med $\geq 50\%$ ($\geq 50\%$ reduktion av produkten av de största perpendikulära diametrarna) utan samtidig progress på andra lokaler. HCG normalt eller faller enligt t1/2.
- Stabil sjukdom: Reduktion av mätbar tumor med $< 50\%$ ($< 50\%$ reduktion av produkten av de största perpendikulära diametrarna) utan samtidig progress på andra lokaler. HCG oförändrat eller faller enligt t1/2.
- Progressiv sjukdom: Ökning av mätbar tumor med $\geq 25\%$, eller tillkomst av nya tumormanifestationer, eller ökning av tumörmarkörer $> 10\%$.
- Ej bedömbart: Objektiv parameter saknas (t ex vid adjuvant behandling) eller ej undersökt vid undersökningstillfället.

SWENOTECA VII, Seminom
Uppföljningsblankett

Svenska patienter SWENOTECA sekretariatet Onkologiskt centrum Universitetssjukhuset i Lund 221 85 LUND	Norska patienter Kontor for klinisk kreftforskning Kreftavdelningen Haukeland Universitetssykehus 5021 Bergen
Klinik, sjukhus	
Läkare	

Personnummer

Namn

Besöksdatum	år mån dag						
Status							
<input type="checkbox"/> inga tecken på sjukdom <input type="checkbox"/> kontralateral testikelcancer							
<input type="checkbox"/> stabil eller minskande resttumör <input type="checkbox"/> annan cancer							
<input type="checkbox"/> recidiv/progress av resttumör (fyll i nedan)							
Senreaktion av behandling år 1, 3 och 5							
Minskad libido	<input type="checkbox"/> nej <input type="checkbox"/> ja	Testosteron	□ □ , □	normalt	förhöjt	lägt	ej utfört
Impotens	<input type="checkbox"/> nej <input type="checkbox"/> ja	SHBG	□	□	□	□	□
Annan	<input type="checkbox"/> nej <input type="checkbox"/> ja, spec.	LH	□	□	□	□	□
	FSH	□	□	□	□	□
		Testosteron substitution	□ nej	□ ja			
Fortsatt behandling (ny beh blankett ifylls vid behov)							
<input type="checkbox"/> ingen <input type="checkbox"/> kirurgi <input type="checkbox"/> högdoskemoterapi med rescue							
<input type="checkbox"/> kemoterapi <input type="checkbox"/> strålbehandling <input type="checkbox"/> annan behandling, spec							

Recidiv	Datum	år mån dag																														
Progress av resttumör																																
<input type="checkbox"/> nej <input type="checkbox"/> ja																																
Lymfkörtelmetastaser <table border="1"> <tr> <th></th> <th>nej</th> <th>ja</th> <th>ej evaluerbart</th> <th>Största metastas (mm x mm)</th> </tr> <tr> <td>Inguinalt</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>_____ x _____</td> </tr> <tr> <td>Iliakalt</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>_____ x _____</td> </tr> <tr> <td>Paraaoortal</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>_____ x _____</td> </tr> <tr> <td>Mediastinalt</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>_____ x _____</td> </tr> <tr> <td>Supraklav</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>_____ x _____</td> </tr> </table>				nej	ja	ej evaluerbart	Största metastas (mm x mm)	Inguinalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____	Iliakalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____	Paraaoortal	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____	Mediastinalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____	Supraklav	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____
	nej	ja	ej evaluerbart	Största metastas (mm x mm)																												
Inguinalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____																												
Iliakalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____																												
Paraaoortal	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____																												
Mediastinalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____																												
Supraklav	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____																												
Extralymfatiska metastaser <table border="1"> <tr> <th></th> <th>nej</th> <th>ja</th> <th>ej evaluerbart</th> <th>Största metastas (mm x mm)</th> </tr> <tr> <td>Lunga</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>_____ x _____</td> </tr> <tr> <td>Lever</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>_____ x _____</td> </tr> <tr> <td>Hjärna</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>_____ x _____</td> </tr> <tr> <td>Skelett</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>_____ x _____</td> </tr> <tr> <td>Annat, spec</td> <td colspan="4"></td> </tr> </table>				nej	ja	ej evaluerbart	Största metastas (mm x mm)	Lunga	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____	Lever	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____	Hjärna	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____	Skelett	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____	Annat, spec				
	nej	ja	ej evaluerbart	Största metastas (mm x mm)																												
Lunga	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____																												
Lever	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____																												
Hjärna	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____																												
Skelett	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____ x _____																												
Annat, spec																																
Symtom eller undersökning(ar) som först signalerar recidiv (flera alternativ kan anges)																																
<input type="checkbox"/> symptom <input type="checkbox"/> CT/MR/UL <input type="checkbox"/> tumörmarkörer <input type="checkbox"/> annat, spec																																

Dödsdatum	år mån dag
Dödsorsak	
<input type="checkbox"/> testikelcancer <input type="checkbox"/> biverkningar i samband med behandling <input type="checkbox"/> annan cancer <input type="checkbox"/> annan orsak	

SWENOTECA VII, SEMINOM Registreringsblankett

Svenske pasienter
Swenoteca sekretariatet
Onkologiskt centrum
Universitetssjukhuset i Lund
221 85 Lund

Norske pasienter
Kontor for klinisk kreftforskning
Kreftavdelingen
Haukeland Universitetssykehus
5021 Bergen

Navn _____
Fødselsdato (d/m/å) _____ Personnr. _____
_____. _____. 19 _____. _____

Sykehus, avd.

Lege

Sykehusnr. _____ Pasientnr. _____

Orchiektomi

nei dag måned år Kontralateral testisbiopsi Spermogram
 ja Dato 20 Cis ikke Cis ikke utført nei ja hvis ja før orchiektomi
 etter orchiektomi

Sykehus Avd. Pat. PAD nr. _____ - _____ år

Orchiektomi hø ve Tumorstørrelse "Utbrent tumor" nei ja
Innvekst i røte testis nei ja mm (Fyller ut bare hvis tumorstørrelse ikke er angitt)
Vaskulær invasjon nei ja uklart

Tumormarkører

Før orchiektomi

Dato	dag	måned	år	AFP	_____	_____	_____	normalt	forhøyet	ikke utført
	20			β-HCG	_____	_____	_____	normalt	forhøyet	ikke utført
				LD	_____	_____	_____	normalt	forhøyet	ikke utført
				PLAP	_____	_____	_____	normalt	forhøyet	ikke utført

Etter orchiektomi (ved definitiv stadieinndeling)

Dato	dag	måned	år	AFP	_____	_____	_____	normalt	forhøyet	ikke utført
	20			β-HCG	_____	_____	_____	normalt	forhøyet	ikke utført
				LD	_____	_____	_____	normalt	forhøyet	ikke utført
				PLAP	_____	_____	_____	normalt	forhøyet	ikke utført

Hormonstatus

Dato	dag	måned	år	Testosteron	_____	_____	_____	normalt	forhøyet	låvt	ikke utført
	20			SHBG	_____	_____	_____	normalt	forhøyet	låvt	ikke utført
				LH	_____	_____	_____	normalt	forhøyet	låvt	ikke utført
				FSH	_____	_____	_____	normalt	forhøyet	låvt	ikke utført

Metastaser

Lymfeknutemetastaser

Inguinalt	<input type="checkbox"/> nei	<input type="checkbox"/> ja	Største metastase (mm x mm)	X	_____	_____	_____	Ekstralymfatiske metastaser			
Iliakalt	<input type="checkbox"/> nei	<input type="checkbox"/> ja		X	_____	_____	_____	Lunge	<input type="checkbox"/> nei	<input type="checkbox"/> ja	
Paraaortalt	<input type="checkbox"/> nei	<input type="checkbox"/> ja		X	_____	_____	_____	Antall lungemetastaser			
Mediastinalt	<input type="checkbox"/> nei	<input type="checkbox"/> ja		X	_____	_____	_____	Skjelett	<input type="checkbox"/> nei	<input type="checkbox"/> ja	
Supraklav	<input type="checkbox"/> nei	<input type="checkbox"/> ja		X	_____	_____	_____	Lever	<input type="checkbox"/> nei	<input type="checkbox"/> ja	

Største metastase (mm x mm)

Lunge nei ja

Antall lungemetastaser

Skjelett nei ja

Lever nei ja

Hjerne nei ja

Annet nei ja

Lokalisasjon _____

Klinisk stadieinndeling

<input type="checkbox"/> CSI	Antall risikofaktorer ²	<input type="checkbox"/> 0 <input type="checkbox"/> 1 <input type="checkbox"/> 2	T-stadium pT ³	<input type="checkbox"/> nei <input type="checkbox"/> ja	<input type="checkbox"/> CSII	<input type="checkbox"/> CSIII	<input type="checkbox"/> CSIV	<input type="checkbox"/> CSMk+
------------------------------	------------------------------------	--	---------------------------	--	-------------------------------	--------------------------------	-------------------------------	--------------------------------

Abdominale lymfeknuter	<input type="checkbox"/> 0 <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D	Gruppering ifølge MRC ⁴	<input type="checkbox"/> small <input type="checkbox"/> large <input type="checkbox"/> very large volume	Prognose ifølge IGCCC ⁵
				<input type="checkbox"/> god <input type="checkbox"/> intermediær <input type="checkbox"/> dårlig

Behandling CSI	<input type="checkbox"/> surveillance	<input type="checkbox"/> adj. karboplatin	<input type="checkbox"/> adj. strålebehandling
Behandling CSII-IV, CSMk+	<input type="checkbox"/> strålebehandling	<input type="checkbox"/> EP <input type="checkbox"/> BEP	<input type="checkbox"/> annen, spes.

Kommentarer

37683

1 Klinisk stadioinndeling: modifisert etter RMH

CS I Ingen tegn til metastaser

CS Mk+ β -HCG er vedvarende forhøyet (reduseres ikke i forhold til sin halveringstid), men ingen påvisbare metastaser

CS II Metastaser begrenset til abdominale lymfeknuter

A maksimal diameter <2 cm

B maksimal diameter 2–5 cm

C maksimal diameter >5–10 cm

D maksimal diameter >10 cm

CS III Metastaser i lymfeknuter over diafragma

For abdominale lymfeknuter gjelder:

0 ingen metastaser

A–D ifølge CS II ovenfor

CS IV Ekstralymfatiske metastaser

For lungemetastaser gjelder:

L₁ ≤3 metastaser, ingen >2cm

L₂ >3 – ≤20 metastaser, ingen >2cm

L₃ ≤20 metastaser, >2cm

L₄ >20 metastaser

For abdominale lymfeknuter gjelder:

0 ingen metastaser

A–D ifølge CS II ovenfor

2 Risikofaktorer

Primærtumor >4 cm, innvekst i rete testis

3 pT4

Tumor invaderer scrotum med eller uten vaskulær/lymfatisk invasjon

4 Gruppering ifølge Medical Research Council

Small volume disease CS Mk+, II_{A–B}, III_{0–A–B}, IV_{0–A–B, L1–L2}

Large volume disease CS II_{C–D}, III_{C–D}, IV_{C–D, L1–L2}

Very large volume disease CS IV_{0–D, L3–L4}; ekstralymfatiske ekstrapulmonale metastaser
(skjelett, lever, hjerne)

5 International Germ Cell Collaborative Consensus Classification

Good-prognosis group

All of the following criteria:

Any primary site

No non-pulmonary visceral metastases

Normal AFP

Any β -HCG

Any LDH

Intermediate-prognosis group

Any of the following criteria:

Any primary site

Non-pulmonary visceral metastases

Normal AFP

Any β -HCG

Any LDH

Poor-prognosis group

No patients classified as poor prognosis

SWENOTECA VII, SEMINOM

Behandlingsblankett

Svenske pasienter
 Swenoteca sekretariatet
 Onkologiskt centrum
 Universitetssjukhuset i Lund
 221 85 Lund

Norske pasienter
 Kontor for klinisk kreftforskning
 Kreftavdelingen
 Haukeland Universitetssykehus
 5021 Bergen

Sykehus, avd.

Lege

Navn _____
Fødselsdato (d/m/å) _____ **Personnr.** _____
 [] . [] . 1 9 [] []
Sykehusnr. [] [] [] **Pasientnr.** [] [] []

Årsak til behandling

adjuvant metastatisk sykdom recidiv

dag måned år

Start av behandling [] . [] . 2 0 []

Avsluttet behandling _____

dag måned år

[] . [] . 2 0 []

Kjemoterapi

carboplatin EP BEP annet _____

Antall kurer [] []

Strålebehandling

paraaortalt paraaortalt + iliakalt annet _____

Fraksjonsdose [] , [] Gy

Targetdose [] , [] Gy

Årsak til avsluttet behandling

ferdig program terapisiktig bivirkninger annen, spes.

Toxicitet¹ Grad 3-4

Hematol. Hb nei ja
 hvite nei ja
 trombocyetter nei ja
 Renal S-kreat nei ja

Perifer neuropati nei ja
 Obstipasjon nei ja
 Infeksjon nei ja
 Annen alvorlig toxicitet nei ja, spes.

Effekt av behandling²

adjuvant behandling CR PR SD PD ikke evaluerbart

Fortsatt behandling

(ruter fyller ut når beslutning er tatt og evt. tilleggsbehandling er gitt)

ingen kjemoterapi, spes. høydosekjemoterapi med rescue
 konsoliderende strålebehandling kirurgi annen behandling, spes.

Konsoliderende strålebehandling

(etter kjemoterapi/kirurgi)

dag måned år
Startdato [] . [] . 2 0 []
Resttumor abdomen pulm annet

Fraksjonsdose [] , [] Gy Targetdose [] , [] Gy

Kirurgi

dag måned år
Dato [] . [] . 2 0 []

Årsak til kirurgi

Resttumor abdomen pulm annet

Recidiv abdomen pulm annet

Annen årsak, spesifiser årsak og lokalisasjon

Sykehus _____ **Avd. Pat.** _____

PAD nr. [] - [] år

PAD nekrose/fibrose seminom annet

Radikal operasjon kirurgi høydosekjemoterapi med rescue
 nei ja nei ja, spes.

Fortsatt behandling etter evt. tilleggsbehandling

(ny Behandlingsblankett fyller ut ved behov)

ingen kirurgi høydosekjemoterapi med rescue
 kjemoterapi strålebehandling annen behandling, spes.

Kommentarer

1 Gradering av toxicitet (WHO 1979)

	Grad 3	Grad 4
Hematologisk (voksne)		
Hemoglobin g/L ⁹	65–79	< 65
Hvite x 10 ⁹ /L	1,0–1,9	< 1,0
Trombocytter x 10 ⁹ /L	25–49	< 25
Urinveier		
S-Kreatinin	5–10 x N	> 10 x N
Neurotoxicitet		
Perifer	Intolerable parestesier og/eller uttalt svakhet	Lammelse
Obstipasjon*	Utspilt buk	Utspilt buk og brekninger
Infeksjon	Alvorlig infeksjon	Alvorlig infeksjon med blodtrykksfall

N = Øvre normalgrense

* = Obstipasjon, inkluderer ikke obstipasjon p.g.a. morfinpreparat

2 Remisjonsvurdering. Effekt av behandling

Komplett remisjon: Samtlige tumormanifestasjoner er fullstendig forsvunnet på CT/MR eller tilsvarende. Normale tumormarkører.

Partiell remisjon: Reduksjon av målbar tumor med $\geq 50\%$ ($\geq 50\%$ reduksjon av produktet av de største perpendikulære diametre) uten samtidig progresjon i andre lokalisasjoner. HCG normal eller er redusert likt t1/2.

Stabil sykdom: Reduksjon av målbar tumor med $< 50\%$ ($< 50\%$ reduksjon av produktet av de største perpendikulære diametre) uten samtidig progresjon i andre lokalisasjoner. HCG uforandret eller er redusert likt t1/2.

Progressiv sykdom: Økning av målbar tumor med $\geq 25\%$, eller tilsynekomst av nye tumormanifestasjoner, eller økning av tumormarkører $> 10\%$.

Ikke evaluerbart: Objektiv parameter savnes (f.eks. ved adjuvant behandling) eller ikke undersøkt ved kontrolltidspunktet.

SWENOTECA VII, SEMINOM

Oppfølgingsblankett

Svenske pasienter
 Swenotece sekretariatet
 Onkologiskt centrum
 Universitetssjukhuset i Lund
 221 85 Lund

Norske pasienter
 Kontor for klinisk kreftforskning
 Kreftavdelingen
 Haukeland Universitetssykehus
 5021 Bergen

Navn _____

Fødselsdato (d/m/å)

		1	9						
--	--	---	---	--	--	--	--	--	--

Personnr.

Sykehus, avd.

Lege

Sykehusnr.

Pasientnr.

Besøksdato dag måned år
 _____ . _____ . 20_____

STATUS:

- ingen tegn til sykdom (NED)
- kontralateral testikkel cancer
- stabil eller minskende resttumor
- annen cancer
- recidiv/progresjon av resttumor (fyll ut nedenfor)

Senreaksjon av behandling år 1, 3 og 5

		normalt	forhøyet	lavt	ikke utført
Testosteron	_____ , _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
SHBG		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
LH		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
FSH		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Testosteron substitusjon		<input type="checkbox"/> nei	<input type="checkbox"/> ja		

Fortsatt behandling (ny Behandlingsblankett fylles ut ved behov)

- ingen kirurgi høydosekjemoterapi med rescue
- kjemoterapi strålebehandling annen behandling, spes.

Recidiv

Dato dag måned år
 _____ . _____ . 20_____

Progresjon av resttumor nei ja

Lymfeknutemetastaser

	nei	ja	ikke evaluert	Største metastase (mm x mm)
Inguinalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	X
Iliakalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	X
Paraortalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	X
Mediastinalt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	X
Supraklav	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	X

Ekstralymfatiske metastaser

	nei	ja	ikke evaluert	Største metastase (mm x mm)
Lunge	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	X
Lever	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	X
Hjerne	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	X
Skjelett	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Annet, spes.				

Symptom eller undersøkelse(r) som først signaliserte recidiv (flere alternativ kan angis)

- symptom CT/MR/UL tumormarkører annet, spes.

Dødsdato dag måned år
 _____ . _____ . 20_____

Dødsårsak

- testikkel cancer bivirkninger i forbindelse med behandling annen cancer annen årsak

Kommentarer

57677